The Role of Transforming Growth Factor Beta in Hepatic Encephalopathy Pathogeneis by McMillin, Matthew Alexander
	  THE ROLE OF TRANSFORMING GROWTH FACTOR BETA  
IN HEPATIC ENCEPHALOPATHY PATHOGENESIS 
 
A Dissertation 
by 
MATTHEW ALEXANDER MCMILLIN 
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,  Sharon DeMorrow 
Committee Members, Cynthia Meininger 
    Pier Luigi Di Patre 
    Russell Sanchez 
Head of Department, Alejandro Arroliga 
 
December 2013 
 
Major Subject:  Neuroscience 	  
Copyright 2013 Matthew Alexander McMillin 	  	  	  	  
	   ii	  
ABSTRACT 
 
 
Hepatic encephalopathy (HE) is a neurological complication that arises 
due to liver dysfunction and is associated with increased circulating ammonia 
and a systemic immune response.  Treatment paradigms have attempted to 
minimize the metabolic and inflammatory consequences of liver failure.  
However, investigations into the specific cell signaling mechanisms between the 
liver and brain that induce these pathological processes are currently lacking.  
Both TGFβ1 and Shh are known to be upregulated in the liver and present in the 
circulation following liver damage.  These studies employed the azoxymethane 
(AOM) model of acute liver failure in mice, the bile duct ligation (BDL) model of 
minimal HE in rats, and patients with liver cirrhosis who had HE to study cell 
signaling and pathological processes present during HE.  Studies of specific 
cellular signaling mechanisms were performed in isolated primary neurons and 
immortalized brain endothelial cells.  All pharmacological manipulations of 
hedgehog signaling, TGFβ signaling, and clodronate-liposome depletion of 
microglia were performed in AOM mice.  Gli1 was upregulated in AOM, BDL, 
and HE patient cortices.  Shh was upregulated in the liver and serum during HE, 
but had no effect on neurological decline.  Liver TGFβ1 signaling was 
upregulated and had increased expression in cortical neurons.  TGFβ1 
suppressed neuronal Gli1 via SMAD3.  The use of neutralizing antibodies 
against TGFβ generated neuroprotection during HE.  The BBB was disrupted 
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during AOM-induced HE and neutralizing antibodies against TGFβ significantly 
reduced permeability.  Studies using bEnd.3 cells found that TGFβ1 suppressed 
Claudin-5 and increased MMP9 through a SMAD3-dependent mechanism.  
Depletion of microglia with clodronate liposomes in AOM mice was protective.  
Cortical CCL3/CCR1 axis signaling was elevated during HE and was reduced 
with neutralizing antibodies against TGFβ.  Also, treatment with neutralizing 
antibodies against TGFβ reduced microgliosis and microglia activation.  CCL3 
KO mice had no changes in neurological decline compared to wild-type mice.  
Elevation of Gli1 or suppression of TGFβ1 was neuroprotective during HE.  
TGFβ1 increased BBB permeability and generated microglia activation and 
microgliosis during HE though this effect was not through the CCL3/CCR1 
signaling axis.  Gli1 or TGFβ1 may be therapeutic targets for the treatment and 
management of HE. 
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1.  INTRODUCTION 
 
The liver is the largest internal organ in the body making up between 2% 
and 3% of total body weight and is one of the most important organs involved in 
maintenance of physiological homeostasis(1).  The liver is also the most highly 
vascularized organ receiving 25% of total cardiac output due to its dual blood 
supply from the hepatic artery and the portal vein(1).  The blood from these two 
sources mixes within hepatic sinusoids before entering the hepatic venous 
system and passing into the systemic circulation.  This association with the 
blood supply allows the liver to perform many functions including metabolism of 
carbohydrates, proteins, and lipids, clearance of toxins and pathogens, and 
immune response regulation(2).  In addition to these, the liver also produces 
bile, regulates plasma proteins and glucose, and is involved in the 
biotransformation of drugs and toxins(3). 
 Damage to the liver disrupts all of the aforementioned processes and 
leads to dysfunction in maintenance of homeostasis.  Liver failure arises from 
both chronic and acute liver insults, which result in differential liver pathology 
and disease processes.  Chronic liver damage is commonly associated with 
hepatitis C, alcoholic cirrhosis, nonalcoholic fatty liver disease, nonalcoholic 
steatohepatitis and hemochromatosis, which collectively affect around 40 million 
people in the United States(4).  On the other hand acute liver failure (ALF) is a 
significantly more rare disorder but is associated with higher mortality(5).  The 
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causes of ALF differ significantly based on geographical location, with ALF in the 
United States and western Europe being predominantly caused by drug-induced 
liver injury, while ALF in other areas is predominantly caused by hepatitis A, B, 
and E(6).   In the United States, acetaminophen-induced toxicity leads to 26,000 
hospitalizations and close to 500 deaths per year(7, 8).  While acetaminophen 
toxification is the leading cause of toxin based ALF in the United States, multiple 
drugs including statins, non-steroidal anti-inflammatory drugs, antituberculosis 
drugs, antibiotics, anti-epileptic drugs, and other drugs have been reported to 
cause ALF(9).  There have been other rare cases of ALF, which result from 
hyperthermic injury, Wilson’s disease, ischemic injury from systemic hypotension 
during sepsis or cardiac failure, Budd-Chiari syndrome, and specific toxin 
exposure such as the Amanita spp mushroom(10). 
While the causes of both chronic liver failure and ALF vary greatly, the 
molecular basis for liver failure is based upon the same general principles.  In 
the case of Wilson’s disease, a rare hereditary condition caused by a loss of 
function mutation in the copper transporting ATPase ATP7B, there is increased 
copper accumulation in the mitochondria of hepatocytes, which causes 
mitochondrial dysfunction with subsequent damage to these cells(11).  During 
nonalcoholic steatohepatitis it has been previously shown that there is an 
upregulation of tumor necrosis factor-alpha (TNFα), which causes apoptosis of 
hepatocytes(12).  Acetaminophen toxicity, on the other hand, leads to 
mitochondria dysfunction and nuclear DNA fragmentation, which cause 
	   3	  
hepatocyte necrosis with subsequent liver failure(13).  Thus, in genetic, chronic, 
and acute liver pathologies that lead to liver failure there is dysfunction and 
death of hepatocytes, which lead to loss of liver function and liver failure. 
Both acute and chronic liver failure have the ability to generate a 
multitude of effects inside and outside the liver.  Inside the liver there is a loss of 
metabolic function, hypoglycemia due to decreased gluconeogenesis, lactic 
acidosis caused by reduced lactate clearance, reduced ammonia clearance, and 
coagulopathy(5).  Outside of the liver there is a systemic inflammatory 
response(14), increased energy expenditure(15), acute lung injury, reduced 
glucocorticoid production(16), increased cardiac output with subclinical 
myocardial injury(17), pancreatitis, kidney dysfunction(18), immune impairment 
increasing susceptibility to sepsis, and immunoparesis(19).  In addition to this, 
the development of a neurological condition called hepatic encephalopathy (HE) 
is evident, which is correlated with cerebral edema and increased intracranial 
pressure(5, 20).  HE is a deadly complication that arises from liver failure and 
has its own unique pathological mechanisms. 
 Due to the fact that liver failure and dysfunction can arise from different 
mechanisms, HE is divided into three main clinical categories.  Type A HE arises 
from ALF, type B HE is caused by portal-systemic shunting with no liver disease, 
and type C is caused by chronic liver disease and cirrhosis(21).  In addition to 
this, HE manifests with four different clinical grades, which are known as the 
West Haven Criteria.  Grade 1 is classified with a lack of awareness, euphoria, 
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anxiety and reduced attention span.  Grade 2 manifests with lethargy, mild 
disorientation for time or place, minor personality changes and inappropriate 
behavior.  Confusion, significant disorientation, and a loss of comprehension of 
verbal stimuli occur at grade 3.  This progresses to grade 4 where a patient will 
stop responding to verbal cues or noxious stimuli and subsequently becomes 
comatose(21).    
While there is no true rodent model to replicate human disease in its 
entirety, there are certain models that have become accepted and used in the 
HE field to help understand and manipulate pathological factors.  Type A HE has 
the greatest number of models, with most of them being developed in rats.  Rat 
models of type A HE anhepatic models include hepatic devascularization(22), 
hepatectomy(23), and portacaval anastomosis with ammonia(24).  Hepatoxin 
models in rats include galactosamine, acetaminophen and thioacetamide(25, 
26).  The only model proven to generate liver failure with consistent neurological 
decline in mice is the hepatotoxin model azoxymethane (AOM) (27).  The AOM 
mouse model is a newer model of HE that has been characterized in both liver 
and brain and displays rapid encephalopathy progression and brain edema(28).  
Since this model is in mice, it allows for greater genetic manipulations to be 
performed.  Type B HE has no models in mice, but can be induced in rats by 
portacaval anastomosis and graded portal vein stenosis(29).  Type C HE again 
has no models in mice, but in rats bile duct ligation (BDL) generates some 
elements of this type of HE.  The BDL rat model of biliary cirrhosis leads to 
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reduced locomotor activity and elevated levels of circulating ammonia, 
characteristics of lower grade HE, 4-6 weeks following surgery(30, 31). 
Interestingly, the amount of liver damage present in patients does not 
always correlate with HE development or severity indicating that other factors 
outside the liver play a significant role in HE(32).  That being said many 
treatments are aimed at reducing ammonia, such as lactulose and 
nonabsorbable antibiotics, which help remove ammonia from the circulation and 
reduce its production by eliminating components of the gut microbiota 
respectively(33, 34).  Outside of this, hypothermia and mannitol can be used to 
reduce intracranial pressure with hypothermia giving the added benefits of 
reducing inflammation and restoring cerebral blood flow(35-39).  Liver 
transplantation is generally the most efficacious treatment for HE, as patients 
who had liver failure with no liver transplantation have only an 18% survival one 
year after developing liver failure, though therapeutics like N-acetylcysteine, 
which is an antioxidant and used to treat acetaminophen toxicity, have been 
shown to significantly improve transplant-free survival to 35%(40).  Even with the 
advances made in liver transplantation and novel therapeutics, recent statistics 
show survival following liver failure to be only around 65%(41, 42).  Thus, the 
development of new therapeutics that are cost effective for the management of 
HE is greatly warranted, but to do so requires greater understanding of the 
mechanisms that cause this disease. 
	   6	  
 The primary mechanism classically thought to be involved in exacerbating 
HE pathology involves increases in circulating and intracranial concentrations of 
ammonia.  Following liver damage and subsequent disruption of the urea cycle, 
levels of ammonia are increased in the circulation.  This increased concentration 
of ammonia is able to enter the brain where astrocytes metabolize this 
molecule(43).  Ammonia metabolism by astrocytes causes metabolic stress in 
astrocytes leading to cytotoxic edema and, in clinical HE, the development of 
Alzheimer’s type II astrocytes in the basal ganglia(44).  Furthermore, low 
concentrations of ammonia have been demonstrated to enhance GABAergic 
neurotransmission while at the same time downregulating glutamatergic 
neurotransmission via postsynaptic downregulation of NMDA receptors(45, 46).  
Thus, there is support that some of the cognitive and motor deficits that are 
present could be caused by suppression of neural circuits and astrocyte 
dysfunction caused by ammonia.  However, there are some significant issues 
that point to other factors playing a more prevalent role in HE.  First of all, 
arterial ammonia levels do not correlate strongly with HE severity in a study of 
cirrhotic patients with severe HE(47).  Also, studies investigating hyperammonia 
have found that patients do express some similarities to HE, such as cerebral 
edema and swelling of astrocytes, but there were also observations of 
ventriculomegaly and atrophy of the cerebral cortex, which are not observed 
during HE(48).  In addition to these structural changes in the brain, ammonia 
has been demonstrated to correlate with increased seizure activity, as patients 
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with generalized tonic-clonic seizures have elevated levels of plasma 
ammonia(49).  Thus, it is apparent that ammonia is not capable of replicating all 
aspects of HE pathology and, because of this, must work in synergism with other 
pathological processes. 
A second hypothesis into the major etiological cause of HE has identified 
inflammation to play a prominent role.  Liver failure due to infection 
demonstrated that both the infection itself as well as the subsequent hepatocyte 
cell death are able to promote a systemic inflammatory response(14, 50).  That 
being said, the cause of liver failure greatly influences the magnitude of the 
inflammatory response that is generated(51).  Patients who had ALF and 
systemic inflammatory response syndrome were more likely to go on to develop 
HE compared to patients with ALF who did not have systemic inflammatory 
response syndrome(52).  In a model of hepatic devascularization, microglia 
activation is observed along with upregulation of proinflammatory cytokines 
TNFα, IL-1β, and IL-6 in the brain(53).  Elevated mRNA expression of 
proinflammatory cytokines has been found to predict increased HE severity and 
correlates with brain edema(54).  These proinflammatory cytokines have been 
demonstrated to be pathogenic as TNFα and IL-1 β receptor gene deletion in 
AOM mice was found to reduce HE onset and subsequent brain edema(55).  In 
addition to this, microglia activation has been observed clinically in patients who 
had ALF from infection from viral hepatitis(56) and in patients with liver cirrhosis 
who died from hepatic coma(57).  Strategies to suppress microglia activation via 
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minocycline administration have been demonstrated to be protective in rats that 
had undergone hepatic devascularization with the subsequent development of 
HE via the suppression of proinflammatory cytokines(54, 58).  Interestingly, 
ammonia also has the ability to induce inflammation and microglia activation and 
could be one mechanism driving progression of HE(57, 59).  However, there is 
also increased lactate in the brain, which has been found to activate microglia 
and lead to release of TNFα and IL-6 from microglia cell cultures(60).  In 
addition to lactate, manganese accumulation occurs in the brains of patients with 
cirrhosis but has not been shown in patients with ALF(61, 62). Manganese has 
been demonstrated to regulate inflammatory cytokine output, hydrogen peroxide 
release, and nitric oxide release from microglia(63, 64).  These studies support 
that there is a significant involvement of inflammation in HE pathology.  
However, at this time there are few studies investigating cell signaling proteins 
that are directly and indirectly involved with inflammation and whose expression 
are upregulated during HE. 
 Sonic hedgehog (Shh) is a mammalian hedgehog protein that has been 
found to play important roles in nervous system development, blood-brain barrier 
(BBB) maintenance, immune function, and liver remodeling following injury(65-
67).  Shh protein is expressed centrally in neurons, oligodendrocytes, and other 
cells, while Indian hedgehog (Ihh) is expressed primarily in the heart and bone 
and Desert hedgehog (Dhh) is expressed in the gonads and peripheral 
nerves(68).  Shh is cleaved into its C and N terminus and secreted from a host 
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cell where the N terminus is the active protein that exerts its effects by binding 
its membrane bound receptor, patched, on a target cell(69, 70).  This removes 
the inhibitory effect of patched on a transmembrane bound effector protein 
called smoothened, which ultimately causes the activation and nuclear 
translocation of the Gli family of transcription factors (71, 72).  In regards to liver 
damage, it has been shown in mice that have ingested ethionine, a hepatotoxin, 
that hedgehog signaling is upregulated in the liver and this upregulation 
increases with exacerbated liver damage(73).  This damage to the liver and 
upregulation of Shh is primarily in hepatocytes and is in response to stimuli that 
cause apoptosis(74).  Shh signaling cannot be transduced in hepatocytes due to 
a lack of patched expression, thus Shh signaling occurs at neighboring and 
distant cells that facilitate liver remodeling(75).  In fact, following BDL it has been 
shown that exosome-enriched microparticles containing hedgehog ligands are 
found in the bile and plasma, supporting that following liver damage hedgehog 
ligands can be released from the liver and induce paracrine signaling at distant 
sites(76).  One of these potential distant sites is the BBB whose endothelial cells 
express hedgehog receptors and were found to have reduced permeability upon 
exposure to hedgehog ligands(66).  In addition to this, the same study found that 
hedgehog signaling was able to reduce proinflammatory cytokine profiles and 
protect against experimental autoimmune encephalomyelitis(66).  Thus, this 
gives support to the view that following liver damage Shh is upregulated in the 
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liver and has the capability to be released to affect distant targets to promote 
both BBB integrity and reduce proinflammatory cytokine expression. 
 Another signaling factor that has been demonstrated to be upregulated 
following liver damage is transforming growth factor beta 1 (TGFβ1).  TGFβ1 is 
a signaling protein involved in many processes, including immune system 
modulation, cell proliferation, cell differentiation, and apoptosis(77, 78).  TGFβ1 
transduces its signal by binding to its receptor TGFβRII, which then 
phosphorylates and forms a dimer with TGFβRI(79).  This receptor tyrosine 
kinase phosphorylates either SMAD2 or SMAD3, which then associate with the 
co-SMAD, SMAD4(80).  This signaling complex translocates to the nucleus 
where it can bind DNA and affect transcription(81).  
In regard to liver damage, TGFβ1 is upregulated following carbon 
tetrachloride (CCl4) or acetaminophen-induced liver damage(82).  In addition to 
this, TGFβ1 mRNA and protein have been found to be expressed in normal, 
cirrhotic, and neoplastic human livers(83).  A majority of research involving 
TGFβ1 in the liver is in regard to fibrosis, as TGFβ1 plays a critical role in liver 
fibrosis initiation(84).  However, more recent studies have found that antifibrotic 
treatments can generate their effects with essentially no effect on TGFβ1(85).  
Also, it has been shown that following 90% hepatectomy subsequent treatment 
with antibodies against TGFβ1 was able to protect LPS-treated rats compared to 
rats treated with LPS alone(86).  Interestingly, hepatic stellate cells but not 
hepatocytes were found to express TGFβ1, while the TGFβ1 receptor, TGFβ 
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receptor 2 (TGFβR2), was found to be expressed in hepatocytes(83).  This 
supports the involvement of paracrine signaling in the liver following damage 
and may indicate that TGFβ1 has the ability to signal at distant sites similar to 
Shh.  In support of this, TGFβ1 has been found to be elevated in the circulation 
of patients with bile duct injury(87).  Interestingly, TGFβ1 has been shown to 
suppress the systemic immune response(88).  Also, there is support in the brain 
that TGFβ1 reduces microglia activation and downregulates inflammatory 
factors(89).  Thus, there is support for TGFβ1 upregulation in the liver following 
liver damage and TGFβ1 in the circulation could be suppressing the systemic, 
and potentially central, immune response. 
 Due to the fact that liver damage upregulates both hedgehog and TGFβ1 
signaling, the current study was aimed at assessing whether following liver 
failure hedgehog and TGFβ1 are released from the liver into the circulation and 
can influence cell-signaling pathways at distant sites.  The overall hypothesis for 
this study is that hedgehog and TGFβ1 are released from the liver following 
damage and these signaling proteins then suppress neuroinflammation during 
HE. 
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2.  GLI1 ACTIVATION AND PROTECTION AGAINST HEPATIC 
ENCEPHALOPATHY IS SUPPRESSED BY CIRCULATING TRANSFORMING 
GROWTH FACTOR β1 IN MICE 
 
2.1.  Overview 
 
The transcription factor Gli1, which can be modulated by hedgehog or 
TGFβ1 signaling, has been shown to be protective in various neuropathies. We 
measured levels of Gli1 in brain tissues from mice, rats, and patients with HE, 
and evaluated how circulating TGFβ1 and hedgehog signaling regulate its 
activation.  Mice were injected with AOM to induce HE, in the presence of Gli1 
hedgehog, or TGFβ1-modulating treatments.  Gli1 was increased in brains of 
AOM mice and in patients with HE compared to controls. Intra-cortical infusion of 
Gli1 Vivo morpholinos exacerbated the neurologic deficits of AOM mice. 
Modulation of hedgehog signaling had no effect on HE neurological decline. 
Levels of TGFβ1 increased in liver and serum of mice following AOM 
administration.  TGFβ neutralizing antibodies slowed neurologic decline 
following AOM administration without affecting liver damage. TGFβ1 inhibited 
Gli1 via a SMAD3-dependent mechanism. Overall, cortical activation of Gli1 
protects mice from HE and TGFβ1 suppresses neural Gli1 via SMAD3 and 
promotes neurologic decline. Strategies to activate Gli1 or inhibit TGFβ1 might 
be developed to treat patients with HE. 
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2.2.  Introduction 
 
HE is a neurological complication that can arise following acute or chronic 
liver damage and is a metabolically-induced, functional disturbance of the 
brain(90).  The most severe form of HE occurs following ALF, which can be 
caused by drug-related liver damage, hyperthermic injury, and toxin 
exposure(5). The neurological decline observed in HE is caused by toxin 
accumulation in the blood.  These toxins have the ability to cross the BBB and 
generate neurotoxic effects in the brain, including swelling of astrocytes, 
cerebral edema, and dysregulation of water balance(91).  Associated with 
impairment of astrocyte function is a decrease in neuronal function, which leads 
to progressive cognitive deficits, motor deficits, and eventually coma(92). 
 Glioma-associated oncogene homolog 1 (Gli1), a member of the Gli 
family of transcription factors, has previously been shown to be protective in 
neurological conditions such as ischemic injury, stroke, and Parkinson’s 
disease(93-95).  Activation of Gli1 is traditionally a downstream consequence of 
the hedgehog pathway, via the activation of smoothened (96).  However, 
signaling outside of the canonical hedgehog pathway can also regulate Gli 
activity, such as TGFβ1 signaling(97-99).  The signaling ligand TGFβ1 binds a 
receptor complex containing TGFβR2 leading to the phosphorylation/activation 
of SMAD3, which translocates to the nucleus and regulates transcription(100).  
Therefore, understanding both canonical hedgehog signaling and non-canonical 
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pathways, such as TGFβ1, is required to elucidate the regulation of Gli 
transcription factors during disease states. 
Currently, studies have not addressed circulating factors released during 
liver failure and their influence on HE brain pathology.  Recent data suggest that 
hedgehog signaling is involved in expansion of liver progenitor cells after injury, 
and thus can play a protective role in the liver itself(101).  The hedgehog ligands 
Shh and Ihh are released from hepatocytes in various models of liver damage, 
where they act on liver myofibroblasts and activate endothelial cells(76, 102).  
Conversely, the TGFβ1 pathway has been assessed in chronic liver disease and 
fibrosis models where it facilitates fibrogenesis while also having anti-
inflammatory effects(103).  Necrotic hepatocytes release TGFβ1 into the local 
microenvironment where it is able to initiate the activation of nearby hepatic 
stellate cells(104).  Furthermore, studies have found that rats with hepatic failure 
have elevated levels of serum TGFβ1(105).  Currently little information exists 
concerning the roles of either cortical hedgehog or TGFβ1 signaling during HE 
pathogenesis. 
 Due to the lack of understanding of neural hedgehog pathway activation 
during HE, as well as the signaling that occurs between the circulation and brain 
in this disorder, this study was aimed at assessing the regulation and effects of 
neural Gli1 activation during HE and to determine how circulating Shh and 
TGFβ1 can influence its activation. 
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2.3.  Materials and Methods 
 
Materials 
 Antibodies against Shh were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  Antibodies against TGFβ1, SMAD3, Gli1, Gli2, and Gli3 were 
purchased from Genetex  (Irvine, CA).  Antibodies for albumin were bought from 
Bethyl Laboratories (Montgomery, TX).  NeuN antibodies were ordered from 
Millipore (Billerica, MA).  Phosphorylated SMAD3 (pSMAD3) and TGFβR2 
antibodies were ordered from Cell Signaling Technology (Danvers, MA).  
Neutralizing antibodies for TGFβ (anti TGFβ) and recombinant TGFβ1 protein 
(rTGFβ1) were purchased from R&D systems (Minneapolis, MN). All primers 
were purchased from SA Biosciences (Frederick, MD).  The Gli1 Vivo-
morpholino (5’- GTGGAGTCATTGGATTGAACATGGC-3’) and mismatched 
Vivo-morpholino (5’- GTGCACTCATTGCATTCAACATCGC-3’) were purchased 
from Gene Tools (Philomath, OR).  Smoothened Vivo-morpholino (5’-
GCCAAACAGCCAACTCAGCAAAAGC-3’) and mismatched Vivo-morpholino 
(5’-GCGAAAGAGGCAACTGACCAAAAGC-3’) were also purchased from Gene 
Tools.  Smoothened agonist (SAG) was purchased from Millipore.  All chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted, and 
were of the highest grade available.     
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Mouse azoxymethane model of hepatic encephalopathy 
Mouse in vivo experiments were performed using male C57Bl/6 mice (25-
30 g; Charles River Laboratories, Wilmington, MA).  Mice were allowed free 
access to drinking water and standard mouse chow and were housed in 
constant temperature, humidity, and 12 hour light-dark cycling.  Mice received a 
single intraperitoneal injection of 100 mg/kg AOM to induce ALF and HE.  
Control animals were injected with an equal amount of saline.  After injection, 
mice were placed on heating pads set to 37°C and under heating lamps to 
ensure they maintained normal body temperature.  Also, mice were supplied 
with hydrogel and rodent chow on their cage floor to ensure they had easy 
access to food and hydration.  After 12 hours and every 4 hours following, mice 
were injected subcutaneously with 5% dextrose in 250 µL of saline to ensure 
that they did not become hypoglycemic.  Mice were removed from the study if 
they exhibited a 20% weight loss.   
Following injection, mice were monitored every two hours (starting at 
eight hours post AOM injection) for body temperature, weight, and neurological 
decline.  Neurological decline was assessed by measuring the pinna reflex, 
corneal reflex, tail flexion, escape response, righting reflex, and ataxia, and with 
each given a score of 0 (no reflex evident), 1 (weak or delayed reflex), or 2 
(intact reflex).  Touching the external auditory meatus with a cotton applicator 
and observing ear retraction or head movement assessed the pinna reflex.  The 
corneal reflex was measured by touching the cornea with a cotton applicator and 
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measuring the blink response.  Tail flexion was measured via tail pinch with 
forceps and assessing tail flexion.  Escape response was measured by tail pinch 
by forceps and a subsequent movement of mice away from stimuli.   Placing the 
mice on their back and measuring the time for them to right themselves 
represented the righting reflex.  Ataxia assessment was performed by observing 
movement activity when the mice were placed on the cage wire bar lid.  The 
data were expressed as numerical values calculated from the summation of 
these six reflexes to give scores between 0 and 12.  Tissue was collected at 
time points prior to onset of neurological symptoms (pre neurological), when 
minor neurological deficits were present (minor neurological) as determined by 
presence of ataxia and weakened reflexes, or at coma, which was defined as a 
loss of the righting and corneal reflexes.  
 
Pharmacological treatment strategies in AOM mice 
Systemic inhibition of the hedgehog pathway in mice was performed 
through the use of the smoothened inhibitor cyclopamine.  Cyclopamine was 
dissolved in 45% (2-hydropropyl)-β-cyclodextrin (HBC) and intraperitoneal 
injections were given for 3 sequential days at 10 mg/kg culminating with injection 
of AOM on the third day.  Control animals were injected with 10 mg/kg 45% HBC 
as vehicle.  In order to suppress the activity of circulating TGFβ, injection of 
TGFβ neutralizing antibodies was performed.  This required a single 
intraperitoneal injection at 1 mg/kg 2 hours prior to AOM injection.  Lastly, in vivo 
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genetic Gli1 expression involved implanting mice with minipumps (Alzet, 
Cupertino, CA) that infused Gli1-Vivo morpholinos directly into frontal cortex at a 
dose of 1 mg/kg/day for 3 days prior to the injection of AOM or vehicle at 
coordinates AP +2.0, ML -2.0, DV -2.5.  For controls, a mismatched Vivo-
morpholino was directly infused into the cortex at 1 mg/kg/day for 3 days prior to 
vehicle or AOM intraperitoneal injection at the same coordinates as the Gli1 
Vivo-morpholinos.  Smoothened Vivo-morpholinos were infused in the same 
manner as the Gli1 Vivo-morpholinos with appropriate mismatched controls. 
SAG intracortical infusion was performed at 10 ng/g/day for 3 days prior to the 
injection of AOM or vehicle at coordinates AP +2.0, ML -2.0, DV -2.5.   
 
In vivo model of chronic liver cirrhosis and minimal hepatic encephalopathy in 
the rat 
 In vivo experiments were performed using the BDL model of chronic 
biliary cirrhosis and subsequent HE using 250g male Sprague Dawley rats.  This 
model is the only validated model for chronic cirrhosis with development of 
HE(26).  For this study, rats were anesthetized and their peritoneal cavity was 
surgically opened.  The common bile duct was isolated and subsequently 
ligated.  Following BDL surgery, the rats were given appropriate postoperative 
monitoring and care and were given normal access to chow and water for 4 
weeks.  At this time point we observed reduced activity levels compared to 
sham-operated controls, but no overt signs of neurological decline were present, 
	   19	  
which is similar to what has been previously reported(106).  Rats were 
euthanized and liver, cortex, cerebellum, and blood were collected for further 
analysis. 
 
Human samples 
Brain tissues from patients who had HE following liver cirrhosis, cirrhotic 
patients without HE or aged-matched controls without liver disease were 
supplied through either the autopsy service from Scott & White Memorial 
Hospital Department of Pathology (Temple, TX) or the New South Wales Tissue 
Resource Centre at the University of Sydney. Physiological details and cause of 
death of these patients can be found below in Table 1.  Immunohistochemistry 
or real-time PCR were performed on these tissues as described below. 
 	  
 Control  
(n=7) 
Cirrhotic with 
HE (n=8) 
Cirrhotic w/o HE  
(n=10) 
Male/Female ratio 
 
6/1 6/2 7/3 
Age (avg ± SEM) 
 
51.1 ± 2.52 59.6 ± 3.93 51.7 ± 2.92 
Median age 
(range) 
 
50 (37-61 yr) 58 (40-75 yr) 56 (40-75 yr) 
Cause of death Cardiac 
(n=7) 
HE (n=8) Cardiac (n=4) 
Respiratory/Toxicity (n=3) 
Blood Loss (n=2) 
Trauma (n=1) 	  	  	  	  
Table 1  Summary of patient treatment groups  
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Neuron isolation 
Primary neurons were isolated from P1 rat pups.  Rats were decapitated 
and whole brains were removed.  Cortex was isolated and meninges and dura 
were surgically removed.  Cortical tissue was mechanically and chemically 
disrupted in a 50% TrypLE and Hank’s buffered salt solution (HBSS) solution 
and filtered through a 100-µm filter.  Neurons were suspended in HBSS 
containing 10% heat-inactivated fetal bovine serum (HIFBS) and pelleted by 
centrifugation at 1400 g.  Neurons were resuspended in Modified Eagle’s 
Medium/Ham’s Nutrient Mixture F12 (DMEM/F12) containing 10% heat-
inactivated fetal bovine serum, 50 U/mL penicillin/streptomycin, and 10 µg/ml 
gentamicin.  Cells were then plated on a 12-well plate with a seeding density of 
750,000 cells per well.  After 24 hours, cells were washed with phosphate 
buffered saline (PBS) and placed into MEM/F12 growth media containing 10% 
HIFBS, 2% B27 growth supplement, 50 U/mL pen/strep, and 10 µg/ml 
gentamycin.  Cells were allowed to grow processes and after 10-14 days were 
treated.  Neuronal treatments include varying doses of rTGFβ1, specific inhibitor 
of SMAD3 (SIS3), and TGFβ neutralizing antibodies.  Cells were lysed and RNA 
or protein was isolated as required.   
 
Liver biochemistry 
 Plasma alanine aminotransferasase and bilirubin were assessed using 
commercially available kits. Alanine aminotransferase (ALT) measurement was 
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performed using a fluoremetric activity assay (Sigma).  Total bilirubin was 
assayed using a total bilirubin ELISA (CusaBio, Wuha, China).  All assays and 
subsequent analyses were performed according to manufacturers’ instructions. 
   
Real-time PCR 
RNA was extracted from tissue or cells and real-time PCR (RTPCR) was 
performed as previously described(107) using commercially available primers 
designed against mouse Gli1, Gli2, Gli3, Shh, TGFβ1, and GAPDH as well as 
rat Gli1 and GAPDH (SA Bioscience, Frederick, MD).  A ΔΔCT analysis was 
performed using vehicle-treated tissue or untreated primary neurons as controls 
for subsequent experiments(108, 109).  Data for all experiments are expressed 
as mean relative mRNA levels ± SEM (n=4). 
 
Immunoblotting 
For serum immunoblots, 10% serum samples were diluted in Laemmli 
buffer and loaded in 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gels.  For tissue western blots 10% SDS-PAGE 
gels were loaded with 10-20 µg of protein diluted in Laemmli buffer.  Specific 
primary antibodies against Shh, TGFβ1, SMAD3, pSMAD3, albumin, and β-actin 
were used along with appropriate fluorescent secondary antibodies (LI-COR, 
Lincoln, NE).  All imaging was performed on an Odyssey 9120 Infrared Imaging 
System (LI-COR).  Data are expressed as fold change in fluorescent band 
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intensity of target antibody divided by β-actin, which was used as a loading 
control.  The values of vehicle or control groups were used as a baseline and set 
to a relative protein expression value of 1.  All treatment groups were 
represented as changes of fluorescent band intensity of target antibody to β-
actin relative to vehicle or control groups.  All band intensity quantifications were 
performed using ImageJ software (National Institutes of Health, Bethesda, MD).  
Data for all experiments were expressed as mean relative protein ± SEM (n=4). 
 
Histology, immunohistochemistry, and immunofluorescence 
Paraffin-embedded livers were cut into 3 µm sections and mounted onto 
glass slides where they were used for hemotoxylin and eosin (H&E) stains or 
immunohistochemistry as described(110).  For brain immunohistochemistry and 
immunofluorescence, free-floating 30 µm sections were prepared.  
Immunohistochemistry for both liver and brain was performed using specific 
antibodies for Gli1, Gli2, Gli3, Shh, and TGFβ1.  The sections were viewed 
using an Olympus BX40 microscope with an Olympus DP25 imaging system 
(Olympus, Center Valley, PA).  Quantification of immunohistochemistry was 
performed by analysis of 4 or more fields per sample with a minimum of 3 
samples per experiment.  Mean staining density was calculated using ImagePro 
software (MediaCybernetics, Rockville, MD) while nuclear translocation was 
manually counted in the same fields.  Immunofluorescence of the brain was 
performed using specific antibodies against Gli1, pSMAD3, TGFβR2 and NeuN.  
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Immunoreactivity was visualized using Dylight 488- or Cy3-conjugated 
secondary antibodies and counterstained with 4',6-diamidino-2-phenylindole 
(DAPI).  Slides were viewed and imaged using a Leica TCS SP5-X inverted 
confocal microscope (Leica Microsystems, Buffalo Grove, IL).   
 
Statistical analysis 
All statistical analyses were performed using Graphpad Prism software 
(Graphpad Software, La Jolla, CA).  Results were expressed as mean ± SEM.  
For data that passed normality tests, significance was established using the 
Student t test when differences between two groups were analyzed, and 
analysis of variance when differences between three or more groups were 
compared followed by the appropriate post hoc test.  If tests for normality failed, 
two groups were compared with a Mann-Whitney U test or a Kruskal-Wallis 
ranked analysis when more than two groups were analyzed.  Differences were 
considered significant when the p value was less than 0.05. 
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2.4.  Results 
 
Gli1 is activated in mouse brain during HE  
The AOM model of HE is characterized by consistent neurological decline 
towards coma.  Therefore, to better understand disease progression, we 
performed molecular analyses at times prior to neurological symptom onset 
(reduced activity but no decline in measured reflexes), where minor neurological 
deficits were evident (deficits in one or more reflexes with ataxia present); and 
once coma was reached (loss of corneal and righting reflexes). These stages of 
neurological decline are shown (figure 1A).  In order to validate that AOM 
injections were generating liver damage, H&E stains and liver biochemistry were 
assessed at various stages in AOM-treated and vehicle-treated mice.  The livers 
from AOM-treated mice displayed progressive liver damage with mice at coma 
having severe parenchymal damage including diffuse necrosis of hepatocytes, 
steatosis of surviving hepatocytes and hemorrhage (figure 1B).  The observed 
histopathological changes were consistent with what has been previously shown 
using this model(28).  Serum enzyme assays for bilirubin and ALT supported 
these liver damage assessments (Table 2).  
The expression of Gli transcription factors was assessed at various time 
points after AOM injection.  Cortical Gli1 mRNA was significantly upregulated in 
AOM mice after development of neurological symptoms and showed greatest 
elevation at coma (figure 1C).   
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Treatment Bilirubin (nmol/ml) ALT (U/L) 
Vehicle 4.60 ± 0.42 10.09 ± 3.82 
AOM 68.39 ± 5.29  * 108.62 ± 20.51 * 
AOM + Cyclopamine 53.01 ± 1.20 *  107.45 ± 16.45 * 
Cyclopamine 4.93 ± 0.10 # 16.75 ± 6.30 # 
AOM + anti TGFβ 79.95 ± 12.33 *  139.07 ± 6.30 * 
anti TGFβ 5.02 ± 0.13 # 9.84 ± 1.31 # 
Mismatched-VM Vehicle 1.56 ± 0.32 # 10.41 + 1.43 # 
Mismatched-VM AOM 57.27 ± 3.22 * 144.24 + 4.11 * 
Gli1-VM Vehicle 1.82 ± 0.19 # 9.03 + 2.50 # 
Gli1-VM AOM 55.59 ± 4.65 *  151.22 + 10.73 * 	  
 
 
 
 
 
 
 
 
 
Table 2 Serum liver enzymes for treated mice   
* = p<0.05 compared to vehicle,  # = p<0.05 compared to AOM 
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Fig. 1.  Acute liver insult led to Gli1 activation in the cortex.  (A) Time course of neurological 
decline present in the AOM model.  Neurological score is a measure of 6 reflexes scored 
between 0 and 2, with a lower score indicating greater neurological decline.  Stages of 
neurological decline are identified on the graph.  (B) Liver damage was assessed using H&E 
histochemistry in AOM- and vehicle-treated mice. (C) Cortical Gli1 mRNA expression was 
assessed after AOM treatment. (D) Gli1 immunoreactivity was assayed after AOM injection.  
Subcellular location of immunoreactivity is indicated by a black arrow (cytoplasmic staining) 
or a red arrow (nuclear staining).  (E) Quantitation of Gli1 immunohistochemistry from 
indicated stages of neurological decline.  Quantifications include relative staining intensity per 
field (left axis) and percentage of Gli1 cells that undergo nuclear translocation (right axis).  (F) 
Neuronal expression of Gli1 in vehicle and AOM cortex was assessed by 
immunofluorescence and counterstained with the neuron marker NeuN.  For mRNA analyses 
and quantitative IHC, data are reported as mean ± SEM (n=4).  *p<0.05 compared to vehicle 
cortex.   
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In addition, there was increased Gli1 immunoreactivity and nuclear 
translocation in the cortex as an early event after AOM injection that was 
significantly elevated in the later stages of neurological decline (figure 1D and 
1E).  Moreover, Gli1 expression was found to co-localize with the neuronal 
marker NeuN in vehicle- and AOM-treated mice, suggesting that Gli1 
upregulation occurs primarily in neurons (figure 1F).  This elevation was not 
observed in the cerebellum of AOM mice (figure 2A).  There were no significant 
changes in cortical Gli2 and Gli3 mRNA expression (figure 2B and 2C), 
immunoreactivity, or subcellular localization (figure 2D and 2E) after AOM 
injection.  Together, these results suggest that Gli1 was the primary Gli 
transcription factor that responded to the neural changes that take place during 
HE.  
 
Gli1 is activated in the cortex during HE due to liver cirrhosis 
To assess whether cortical Gli1 activation also occurs in HE as a result of 
chronic liver failure, we employed a rat model of BDL.  Four weeks after BDL 
surgery, rats have mild cognitive deficits as well as elevated levels of 
ammonia(106), indicative of early HE.  Consistent with the early time points of 
AOM-treated mice, Gli1 mRNA expression and immunoreactivity were relatively 
unchanged after BDL (figure 3A and 3B).  However there was increased Gli1 
nuclear translocation after BDL surgery, indicating an increase in Gli1 activity 
(figure 3B and 3C). 
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Fig. 2.  Gli1, Gli2, and Gli3 mRNA expression and nuclear translocation.  (A) RTPCR analysis 
for Gli1 mRNA expression in the cerebellum.  (B) Timecourse cortex analysis for Gli2 mRNA 
expression as assessed via RTPCR.  (C) RTPCR analysis of Gli3 mRNA expression in 
timecourse cortex.  (D) Gli2 protein localization in timecourse cortex using 
immunohistochemistry with inset displayed in right panel.  (E) Immunohistochemistry for Gli3 
protein localization in both vehicle and timecourse AOM cortex.  For mRNA analyses, data was 
reported as mean ± SEM (n=4). 	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To ensure that these findings were also present in clinical cases of HE, 
Gli1 expression was assessed in the cortex and cerebellum of cirrhotic patients 
with HE, cirrhotic patients without evidence of HE, and patients without any sign 
of liver failure.  Cortical Gli1 mRNA was only upregulated in cirrhotic patients 
with HE (figure 3D), suggesting that neurological symptom onset was the 
primary factor involved in Gli1 mRNA expression upregulation.  Furthermore, 
Gli1 immunoreactivity was evident predominantly in the cytoplasm of control 
patients, in HE patients there was significantly increased nuclear localization and 
immunoreactivity of Gli1 suggesting greater Gli1 activation in HE patients (figure 
3E and 3F).  Gli2 and Gli3 were assessed in both BDL rats and cirrhotic patients 
with no significant change in gene regulation or nuclear translocation (data not 
shown).  Taken together, these data demonstrate that following liver cirrhosis 
and subsequent HE that there was increased cortical Gli1 activity. 
 
Gli1 inhibition in the cortex aggravated HE neurological decline 
In an effort to identify if cortical Gli1 is involved in HE pathogenesis, Gli1 
protein expression was reduced by intracortical infusion of Gli1 Vivo-Morpholino 
(VM) sequences.  Gli1 protein expression was knocked down adjacent to the 
infusion site in the cortex (figure 4A).  Furthermore, intracortical Gli1-VM infusion 
significantly exacerbated neurological decline observed after AOM injection 
(figure 4B) and shortened the time to coma (figure 4C) compared to mice 
pretreated with mismatched-VM.  Interestingly, there were no observable 
	   30	  
 
Fig. 3.  Cortical Gli1 was activated during HE due to liver cirrhosis.  (A) Cortical Gli1 mRNA 
expression in sham and 4-week BDL rats.  (B) Cortical Gli1 immunoreactivity in sham and 4-
week BDL rats.  Subcellular localization is demonstrated by a black arrow (cytoplasmic 
staining) or red arrow (nuclear staining).  (C) Quantitation of Gli1 immunohistochemistry 
from sham and 4 week BDL cortex.  (D) Cortical Gli1 expression was assessed in control 
patients (n=7), cirrhotic patients without HE (n=10), and cirrhotic patients with HE (n=8).  
Data is expressed as mean ± SEM.  *p<0.05 compared to control cortex.  (E) Cortical Gli1 
immunoreactivity in clinical HE patients and controls.  Subcellular location is indicated by 
black arrow (cytoplasmic staining) or red arrow (nuclear staining).  (F) Quantitation of Gli1 
immunohistochemistry from control cortex and HE cortex from patient tissue.  For mRNA 
analyses, data are reported as mean ± SEM (n=4).  For quantitative IHC analyses, data are 
reported as mean ± SEM (n=3).  *p<0.05 compared to sham cortex or control cortex. 	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differences in liver damage between these treatment groups as demonstrated by 
H&E staining (figure 4D) and biochemical analyses (Table 2).  Together, these 
data support Gli1 to be a neuroprotective protein that is upregulated as a 
protective mechanism during HE.  
 
 
 
Fig. 4.  Suppression of Gli1 expression exacerbated neurological decline.  Mice were 
infused with Gli1-VM or mismatched-VM into the cortex 3 days prior to AOM injection.  (A) 
Cortical Gli1 knockdown was validated by Gli1 immunofluorescence (red) near the infusion 
site (white arrow) with DAPI (blue) used as a counterstain. (B) Neurological decline was 
assessed using neurological score as previously described.  Gli1-VM treatment significantly 
worsened neurological decline in AOM mice compared to mismatched-VM mice (p=.0435).  
(C) Time to coma in hours of Gli1-VM infused AOM-treated mice and mismatched-VM 
infused, AOM-treated mice.  (D) Liver damage was assessed in Gli1-VM and mismatched-
VM mice by H&E histochemistry. Data are reported as mean ± SEM (n=8).  *p<0.05 
compared to mismatch morpholino cortex. 	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Circulating TGFβ1, but not Shh, may be involved in the neurological decline 
during HE 
In order to determine if neural Gli1 was elevated as a downstream 
consequence of hedgehog signaling, Shh expression was assessed.  Following 
AOM treatment, Shh mRNA and protein were elevated in the liver (figure 5A and 
5B), present in the serum (figure 5C), though unchanged in the brain (figure 5D).  
Pretreatment with cyclopamine, a smoothened antagonist, prior to AOM  
Fig. 5.  Shh expression was elevated in the liver but not the brain following AOM 
treatment. (A) Liver Shh mRNA expression was assessed in vehicle and AOM-treated 
mice by RTPCR.  (B) Immunohistochemistry for Shh in vehicle and AOM livers.  (C) 
Immunoblots were performed to assess the presence of Shh protein in the serum of 
vehicle and AOM-treated mice.  Albumin was used as a loading control.  (D) Cortical Shh 
protein expression was measured in AOM-treated mice compared to controls with β-actin 
used as a loading control.  For protein and mRNA analyses, data was reported as mean ± 
SEM (n=4).  * p<0.05 compared to vehicle liver. 
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did not significantly affect neurological decline (figure 6A), time to coma (figure 
6B), or liver damage (Table 2 and figure 6C).  However, cyclopamine was able 
to reduce circulating Shh (figure 6D) and slightly dampen cortical Gli1 mRNA 
expression although it is still elevated above vehicle (figure 6E).  This gives 
support that cyclopamine inhibited the hedgehog pathway but had no effects on 
Fig. 6.  Cyclopamine treatment had no significant effect on HE progression.  (A) The 
neurological decline of AOM mice and AOM mice treated with cyclopamine (Cyclo).  
Neurological decline was assessed using the neurological score as previously described. 
(B) Time to coma in hours was assessed in AOM and AOM + Cyclo mice. (C) Liver 
damage was assessed by H&E histochemistry in mice were treated with vehicle, AOM, 
AOM + Cyclo, and Cyclo.  No significant differences between AOM mice and AOM mice 
injected with Cyclo were observed. (D) Serum immunoblots were performed for Shh in 
mice treated with vehicle, AOM, AOM + Cyclo, and Cyclo.  (E) Cortical Gli1 mRNA 
expression in mice treated with vehicle, AOM, AOM + Cyclo, and Cyclo.  For mRNA 
analyses, data were reported as mean ± SEM (n=4).  * p<0.05 compared to vehicle 
cortex.  # p<0.05 compared to AOM cortex. 
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HE pathogenesis.  To ensure that direct neural modulation of hedgehog 
signaling does not effect HE, smoothened agonist (SAG) or smoothened-VM 
were infused intracortically.  Treatment with smoothened-VM generated no 
effect on time to coma and Gli1 immunoreactivity was still upregulated in the 
cortex of AOM mice (figure 7A and 7B).  Also, SAG treatment had no effect on 
time to coma but did increase Gli1 immunoreactivity (figure 7C and 7D).  
Fig. 7.  Smoothened Vivo-morpholino and SAG treatment did not significantly affect HE 
neurological decline.  (A) Time to coma in hours of mice cortically infused with 
smoothened-VM or mismatch-VM (n=4 per group).  (B) Gli1 immunohistochemisty in 
vehicle- and AOM-treated mismatch-VM and Smo-VM.  (C) Time to coma in hours for 
mice with cortical infusions of SAG or PBS (n=4 per group).  (D) Gli1 
immunohistochemisty in vehicle- and AOM-treated PBS and SAG mice.   
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  Due to the fact that systemic and central modulation of smoothened had 
no effect on HE pathogenesis, we assessed the effects of TGFβ1 signaling on 
Gli1 activation and neurological decline.  Liver TGFβ1 mRNA expression was 
significantly elevated following AOM injection compared to controls (figure 8A).   
Furthermore, increased TGFβ1 immunoreactivity was found in the livers of 
AOM-treated mice versus controls (figure 8B).  TGFβ1 immunoreactivity 
occurred predominantly in albumin-positive cells in AOM mice, giving support 
that this upregulation is hepatocyte derived (figure 8C).  In addition to this, 
TGFβ1 was present in serum of AOM-injected mice, but at undetectable levels 
in control serum (figure 8D).  Due to the fact that TGFβ1 was upregulated in the 
liver and increased in the circulation, we wanted to determine if TGFβ1 was 
elevated in the brain.  Cortical TGFβ1 protein expression was significantly 
elevated in AOM-injected mice compared to controls (figure 8E).  This increase 
in protein did not coincide with increased cortical TGFβ1 mRNA expression 
(figure 8F), suggesting that increased cortical TGFβ1 protein may not be derived 
from local increases in TGFβ1 gene expression but rather systemic increases in 
TGFβ1. 
 
TGFβ1 modulation in primary neuronal cultures directly affected Gli1 expression 
via a SMAD3-dependent mechanism 
In order to investigate the interaction between TGFβ1 and Gli1, in vitro  
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Fig. 8.  TGFβ1 expression was upregulated in the liver and increased in the brain 
following HE. (A) Liver TGFβ1 expression was assessed in vehicle and AOM-treated mice 
by RTPCR (B) and immunohistochemistry.  (C) TGFβ1 and albumin colocalization in 
vehicle and AOM livers using immunofluorescence.  DAPI was used as a nuclear stain.  
(D) Serum TGFβ1 in vehicle and AOM-treated mice by immunoblotting with albumin used 
as a loading control.  (E) Cortical TGFβ1 protein expression in vehicle and AOM-treated 
mice.  (F) Cortical TGFβ1 mRNA expression in vehicle and AOM-treated mice.  For 
protein and mRNA analyses, data are reported as mean ± SEM (n=4). 	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studies using primary cells were employed.  Because TGFβR2 expression was 
found to colocalize with the neuron marker NeuN in the cortex of vehicle and 
AOM mice (figure 9A), we limited our in vitro studies to primary neuronal 
cultures.  Treatment of neurons with rTGFβ1 for 24 hours suppressed Gli1 
mRNA expression in a dose-dependent manner (figure 9B). Furthermore, 
treatment of neurons with rTGFβ1 (0.5 ng/ml) suppressed Gli1 mRNA from 3 
hours to 24 hours (figure 9C).  This demonstrates that low concentrations of 
rTGFβ1 can generate substantial effects on Gli1 mRNA expression.  
Conversely, treatment of neurons with neutralizing antibodies against TGFβ 
upregulated Gli1 mRNA expression at the 24-hour time point (figure 9D).  
Finally, treatment of neurons with SIS3 was able to reverse Gli1 suppression by 
rTGFβ1 demonstrating that SMAD3 is required to propagate the suppressive 
effect of TGFβ1 on Gli1 expression (figure 9E). 
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Fig. 9.  TGFβ1 suppressed cortical Gli1 through a SMAD3-dependent mechanism.  (A) 
TGFβR2 immunofluorescence in vehicle and AOM cortex costained with NeuN and the 
nuclear stain DAPI. (B) Gli1 mRNA expression in neurons treated with various 
concentrations of rTGFβ1 for 24 hours. (C) Neurons were treated with 0.5 ng/ml of rTGFβ1 
for 1, 3, 6, 12, or 24 hours and assessed for Gli1 mRNA expression.  (D) Neurons were 
treated with TGFβ neutralizing antibodies (anti-TGFβ) and Gli1 mRNA expression was 
measured.  (E) Neurons co-treated with rTGFβ1 and the SMAD3 inhibitor SIS3 and Gli1 
mRNA expression was assessed.  *p<0.05 compared to untreated neurons.  #p<0.05 
compared to 0.5 ng/ml rTGFβ1.  &p<0.05 compared to 0.5 ng/ml rTGFβ1 + 1 µM SIS3.  For 
mRNA analyses, data are reported as mean ± SEM (n=4).	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Fig. 10.  Treatment of AOM mice with TGFβ neutralizing antibodies was neuroprotective.  A) 
Mice pretreated with TGFβ neutralizing antibodies (anti TGFβ) prior to AOM injection had 
significantly lessened neurological decline (p=.0140).  Neurological decline was assessed 
using the neurological score as previously described.  (B) Time to coma for vehicle, AOM, 
AOM + anti-TGFβ, or anti-TGFβ mice. (C) H&E stains for livers from vehicle, AOM, AOM + 
anti-TGFβ, or anti-TGFβ mice.  (D) Positive immunoreactivity of cortical phospho-SMAD3 in 
vehicle, AOM, AOM + anti-TGFβ, or anti-TGFβ mice.  (E) Cortical Gli1 mRNA expression in 
vehicle, AOM, AOM + anti-TGFβ, or anti-TGFβ mice.  For protein and mRNA analyses, data 
are reported as mean ± SEM (n=4).  For time to coma and neurological decline analyses, 
data are reported as mean ± SEM (n=12).  *p<0.05 compared to vehicle liver or vehicle 
cortex.  #p<0.05 compare to AOM cortex. 	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TGFβ1 modulates the neurological decline in AOM-treated mice 
In order to assess if inhibiting TGFβ1 in vivo could alleviate the symptoms 
of HE, mice were treated with TGFβ neutralizing antibodies prior to the injection 
of AOM.  This treatment significantly delayed neurological decline (figure 10A) 
and increased the time taken to reach coma (figure 10B) compared to mice 
treated with AOM alone. H&E stains and liver biochemistry analyses found no 
definitive differences in damage between the livers of AOM-treated mice and 
those pretreated with TGFβ neutralizing antibodies (figure 10C and Table 2).   
AOM-treated mice had increased phosphorylated SMAD3 expression compared 
to mice pretreated with TGFβ neutralizing antibodies or vehicle controls (figure 
10D).  Furthermore, pretreatment with TGFβ neutralizing antibodies prior to 
AOM injection increased Gli1 mRNA expression to a greater degree than mice 
treated with AOM alone (figure 10E).  
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2.5.  Discussion 
 
 HE is a serious neurological complication that arises following liver 
disease(90).  Currently, HE has few effective treatments and thus the need to 
identify targets for potential therapeutics is very important.  Here we 
demonstrate that i) Gli1 is upregulated in the neocortex in rodent models of HE 
and in human autopsy samples from patients with HE, and is neuroprotective 
and ii) circulating TGFβ1 exacerbates HE neurological decline via suppression of 
Gli1 expression through a SMAD3-dependent pathway.  Taken together, our 
data suggest that strategies to increase cortical Gli1 expression and/or inhibit 
TGFβ1 signaling may prove beneficial for the treatment of HE. 
The data presented demonstrate that cortical Gli1 was activated in 
rodents and patients with HE.  Furthermore, inhibiting Gli1 expression using VM 
technology exacerbated neurological decline, suggesting that Gli1 is exerting a 
neuroprotective effect during HE.  Similar upregulation of Gli1 has been 
observed in other pathological brain states.  For example, following cortical 
freeze injury or intracortical lipopolysaccharide injection, Gli1 induction was 
present and dependent on the inflammatory process generated by the 
injury(111).  In addition, inhibition of Gli1 expression led to significant increases 
in infarct volume following ischemia(94).  The use of polydatin, an anti-
inflammatory agent, to treat experimentally induced stroke stimulated Gli1 
expression and was able to reduce acute brain injury damage(95).  These 
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studies demonstrate that Gli1 was upregulated during brain pathologies and was 
neuroprotective, which supports the findings of the current study on HE. 
Canonical hedgehog signaling has been shown to be upregulated during 
liver injury, liver regeneration and in a number of liver diseases(112).  Following 
liver damage, there is increased production of growth factors such as epidermal 
growth factor, platelet-derived growth factor and TGFβ1, which induce liver cells 
to produce hedgehog ligands(113-115).  This leads to increased paracrine 
hedgehog signaling in the liver, which has been shown to be protective in 
cholestatic liver injury and facilitate liver regeneration after partial 
hepatectomy(113, 116).  Indeed, inhibiting hedgehog signaling in the liver with 
cyclopamine disrupts liver regeneration, causes apoptosis of myofibroblasts and 
decreases cell survival of hepatic stellate cells(116-118).  The data presented 
here demonstrated that while Shh expression was increased in the liver and 
bloodstream following injection of AOM, inhibiting canonical hedgehog signaling 
did not significantly affect liver damage across all metrics measured.  This may 
be due to the acute and severe nature of the AOM model.  Furthermore, 
inhibition of hedgehog signaling with cyclopamine had no effect on neurological 
decline even though the route and dose of cyclopamine treatment had 
previously been shown to inhibit brain hedgehog signaling(119).  Treatment of 
AOM mice with SAG or with smoothened-VM validated the results from 
cyclopamine-treated mice.  Together, these findings indicate that the increased 
cortical Gli1 expression during HE, and subsequent neuroprotection, may be 
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due to other unidentified signaling factors, rather than canonical hedgehog 
signaling.  Understanding of the mechanisms by which Gli1 is activated in the 
brain is currently lacking and warrants further investigation.  
Another interesting finding was that TGFβ1 was upregulated in 
hepatocytes and was present in the serum following liver damage.  Interestingly, 
inhibition of circulating TGFβ1 via TGFβ-specific neutralizing antibodies delayed 
neurological decline in AOM mice.  The deleterious effect of TGFβ1 in the brain 
of AOM-treated mice might be related to its role of promoting inflammation(120).  
In support of this concept, the pathogenic inflammation present in a mouse 
model of multiple sclerosis was dependent on TGFβ1 production in the 
CNS(121).  It is becoming evident that HE is dependent on a neuroinflammatory 
response.  Recent studies have demonstrated that microglia become activated 
in experimental hyperammonemia in rats and in patients who have HE(57).  
Furthermore, it has been shown that liver failure due to hepatic 
devascularization leads to an increase of proinflammatory cytokines that 
correlates to microglia activation(53).  Additionally, mice that have an interleukin-
1β or tumor necrosis factor alpha gene deletion have slower HE progression 
compared to wild-type mice(55).  Since TGFβ1 can regulate neuroinflammation 
seen in other neurological disorders, TGFβ1 may play a role in 
neuroinflammation observed following ALF.  
Here we demonstrated that TGFβ1 had an inhibitory effect on cortical Gli1 
expression via a SMAD3-dependent mechanism. In contrast, previous studies 
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showed that TGFβ1 positively regulates Gli1 in pancreatic adenocarcinoma 
cells(97, 98).  The differences in response of Gli1 expression to TGFβ1 may lie 
in the cell type (i.e. neuronal versus pancreas) and/or the transformation status 
(i.e. non-malignant versus cancerous) of the cell.  For example, Gli1 regulates 
the cell cycle through cyclin D2 expression, which is more evident in cancer cells 
than in mature neurons that do not proliferate(122). Also, the finding that 
neurons elevated Gli1 mRNA expression when treated with neutralizing 
antibodies against TGFβ  suggests that TGFβ1 is expressed endogenously in 
neurons.  However, the findings that cortical TGFβ1 mRNA expression was not 
significantly changed in AOM mice provide evidence that circulating TGFβ1 
played a more prominent role in Gli1 suppression.  That being said, our data 
does not rule out a role for posttranslational mechanisms in the expression of 
TGFβ1 in the cortex and thus, studies to answer this definitively are warranted.  
One of the clinical features of ALF may be a loss of BBB integrity(123), 
which can increase toxin entry into the brain(124).  Since our data indicate that 
there is increased cortical TGFβ1 protein after AOM injection, without a 
concomitant increase in TGFβ1 transcriptional activity, it is reasonable to 
assume that the cortical TGFβ1 observed is peripherally derived. In addition, 
systemic treatment of mice with TGFβ neutralizing antibodies, which should not 
penetrate the BBB due to their high molecular weight(125), inhibited TGFβ1 
activity in the circulation and protected against neurological decline.  
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Furthermore, TGFβ1 itself has been shown to inhibit proliferation of brain 
endothelial cells, which can disrupt BBB repair(126). Taken together, we 
propose that circulating TGFβ1 can induce TGFβ1 signaling in the brain and this 
may influence the BBB during HE.  
In conclusion, the data presented demonstrate that Gli1 upregulation in 
cortical neurons occurs during HE and is protective against neurological decline 
seen during HE.  In addition, there is release of hedgehog and TGFβ1 ligands 
from the liver, with TGFβ1 contributing to an increase of HE pathogenesis 
through neuronal suppression of Gli1.  A working model of the liver-brain 
signaling axis as determined in this study is displayed in figure 11.  This study 
demonstrated that suppressing circulating TGFβ1, or increasing cortical Gli1 
activation, could serve as a potential therapeutic strategy for HE treatment.  
Furthermore, our findings suggest that targeting of the TGFβ1/Gli1 signaling axis 
could lend itself as a treatment strategy for other neurological disorders where 
inflammation and metabolic disturbances contribute to pathology. 
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Fig. 11.  Proposed working model of liver-brain signaling axis following liver damage.  AOM is 
metabolized by the hepatocytes in the liver, which leads to their damage and death and eventual 
hepatic failure.  This causes the release TGFβ1 and possibly other factors from the liver into the 
bloodstream.  TGFβ1 plays a deleterious role by suppressing Gli1 mRNA in the cortex and 
exacerbating neurological decline.  Other factors must lead to increases of cortical Gli1 activity, 
as hedgehog signaling cannot account for its upregulation and activation.  These signaling 
factors that activate Gli1 may be either liver-derived or could be the result of neural signaling 
cascades.  Treatments designed to reduce TGFβ1 activity or increase neural Gli1 could be 
efficacious in the treatment of HE.	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3.  TGFβ1 EXACERBATES BLOOD-BRAIN BARRIER PERMEABILITY IN A 
MOUSE MODEL OF HEPATIC ENCEPHALOPATHY VIA 
DOWNREGULATION OF CLAUDIN-5 AND UPREGULATION OF MMP9 
	  
3.1.  Overview 
 
Recent studies have found vasogenic brain edema to be present 
following ALF and that edema is dependent upon increased MMP9 activity and 
tight junction downregulation.  Thus, the objective of this study was to assess if 
circulating TGFβ1 is driving changes in tight junction expression and MMP9 
activity following ALF.  BBB permeability was assessed via Evan’s blue 
extravasation.  Monolayers of bEnd.3 cells were treated with rTGFβ1 and 
permeability was assessed via FITC-dextran diffusion.  BBB permeability was 
increased in ALF mice at 18 hours following AOM injection.  Treatment of 
bEnd.3 cells with rTGFβ1 led to a decrease in Claudin-5 expression as well as 
elevation of MMP9 expression.  Both the downregulation of Claudin-5 and 
upregulation of MMP9 were attenuated following co-treatment with a SMAD3 
inhibitor.  AOM-treated mice injected with neutralizing antibodies against TGFβ 
demonstrated significantly reduced BBB permeability. BBB permeability is 
induced in mice that undergo AOM-induced liver failure and this can be 
ameliorated by reducing circulating TGFβ1, which leads to increased Claudin-5 
and downregulated MMP9 in brain endothelial cells.  
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3.2.  Introduction 
 
 ALF can lead to many detrimental effects outside the liver, which can 
include a systemic inflammatory response, increased energy expenditure and 
catabolism, multiorgan failure and HE(5, 14, 15).  HE is associated with cerebral 
accumulation of ammonia, which leads to the development of cytotoxic brain 
edema in astrocytes.   This cytotoxic edema leads to the generation of 
Alzheimer’s Type II astrocytes in the basal ganglia of patients which is a clinical 
marker of this disease(91, 127).  However, for metabolites and ammonia to 
readily enter the brain and generate these effects, the BBB, which is not 
permeable in normal physiological conditions, must be disrupted(123). 
Microvascular endothelial cells that line the vasculature of the BBB are 
significantly different from other endothelial cells as they lack fenestrations, have 
more extensive tight junctions, and have reduced pinocytic vesicular 
transport(128).  Tight junctions, which are functional barriers created by joining 
together endothelial cells, are made up of cytoplasmic accessory proteins (zona 
occludens-1, -2, and -3) which anchor the actin cytoskeleton to transmembrane 
proteins (Claudins, and occludin)(129).  While direct dysregulation of tight 
junctions can cause vasogenic edema, matrix metalloproteinases (MMP) have 
also been demonstrated to digest tight junction proteins, which allows for 
multiple levels of BBB dysregulation(130).  During ALF, decreased zona 
occludens-2 protein expression has been shown to precede increased BBB 
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permeability(131).  Furthermore, Claudin-5 and occludin have been shown to be 
decreased in the brains of mice with HE(124). MMP9 upregulation has been 
identified as having a causative role in the subsequent permeabilization of the 
BBB at later stages of HE(132).  This gives strong support that BBB permeability 
does occur during HE, however, the specific signaling pathways influencing the 
BBB during HE are not well classified at this time and warrant investigation. 
 TGFβ1 is a signaling protein involved in many processes, including 
immune system modulation, cell proliferation, cell differentiation, and 
apoptosis(77, 78).  In HE it has been demonstrated that TGFβ1 is found in the 
circulation of rats with fulminant hepatic failure(105) and we have found it 
present as well in a mouse model of liver toxin injury.  In regards to the BBB, 
evidence exists to suggest that TGFβ1 can directly affect endothelial cell 
permeability.  Lung endothelial cells grown in monolayers treated with TGFβ1 
demonstrated significantly increased permeability(133) following treatment.  
Also, retinal endothelial cells treated with TGFβ1 were found to increase MMP9 
expression, which subsequently increased permeability of these endothelial 
cells(134).  
 The hypothesis of the current study is that the BBB is disrupted during HE 
and that circulating TGFβ1 contributes to increased vascular permeability of the 
BBB via disruption of tight junctions and upregulation of MMP9.  These 
combined mechanisms would allow a greater degree of toxin entry into the brain 
and exacerbate the pathogenesis of HE. 
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3.3.  Materials and Methods 
 
Materials 
Immortalized mouse brain endothelial cells (bEnd.3 cells) were purchased 
from American Type Culture Collection (Manassas, VA).  24 well transwell 
inserts were purchased from Corning (Tewksbury, MA).  Antibodies against 
MMP9 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) 
Antibodies against Claudin-5 were purchased from Invitrogen (Grand Island, 
NY).  Antibodies against albumin used for immunocytochemistry were 
purchased from Genetex  (Irvine, CA).  Antibodies for tissue 
immunohistochemistry against albumin were bought from Bethyl Laboratories 
(Montgomery, TX).  Neutralizing antibodies for TGFβ (anti TGFβ) and 
recombinant TGFβ1 protein (rTGFβ1) were purchased from R&D systems 
(Minneapolis, MN).  SMI71 antibodies were purchased from Covance (Princeton, 
NJ).  All primers were purchased from SA Biosciences (Frederick, MD).  
GW788388 was purchased from Tocris Bioscience (Minneapolis, MN).  All other 
chemicals were purchased from Sigma-Aldrich (St. Louis MO) unless otherwise 
noted, and were of the highest grade available.     
 
Experimental animals and hepatic encephalopathy model 
Mouse in vivo experiments were performed using male C57Bl/6 mice (25-
30 g; Charles River Laboratories, Wilmington, MA).  Mice were allowed free 
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access to drinking water and standard mouse chow and were housed in 
constant temperature, humidity, and 12 hour light-dark cycling.  Mice received a 
single intraperitoneal injection of 100 mg/kg AOM to induce ALF and HE.  
Control animals were injected with an equal volume of saline.  After injection, 
mice were placed on heating pads set to 37°C and under heating lamps to 
ensure they maintained normal body temperature.  Also, mice were supplied 
with hydrogel and rodent chow on their cage floor to ensure they have easy 
access to food and hydration.  After 12 hours and every 4 hours following, mice 
were injected subcutaneously with 500µl of a 5% dextrose solution to ensure 
that they did not become hypoglycemic.  Mice were removed from the study if 
they underwent a 20% weight loss.   
 In order to suppress the activity of circulating TGFβ, injection of TGFβ 
neutralizing antibodies (R&D Systems, Minneapolis, MN) was performed.  This 
required a single intraperitoneal injection at 1 mg/kg 2 hours prior to AOM 
injection.  Mice in all groups were euthanized at indicated timepoints or were 
allowed to progress to coma (loss of both righting and corneal reflexes). 
 
In vivo BBB permeability measurements 
To assess in vivo permeabilization of the BBB in the AOM HE mouse 
model a modified Evan’s blue dye assay was performed in vehicle and AOM 
mice(135).  Briefly, mice were anesthetized with isoflurane inhalation and an 
incision was made in the neck to expose the carotid artery.  Evan’s blue dye was 
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injected (5mg/ml; 500µl) and allowed to circulate for 20 minutes at which time 
mice were euthanized. Mice were then perfused transcardially with 50ml ice cold 
PBS, the meninges were removed and the brain was blotted dry. The brain stem 
and cerebellum were removed and the two remaining hemispheres were 
homogenized with 1.5 ml ice-cold trichloroacetic acid (50% v/v) in a glass 
homogenizer. The resulting homogenates were centrifuged for 10 minutes at 
10,000 g and absorbance of the supernatant was read at 620nm. In vivo 
permeabilization was measured in mice treated with neutralizing antibodies 
against TGFβ as well. 
 
In vitro permeability assessments 
In order to assess endothelial cell permeabilization in vitro, monolayers of 
bEnd.3 cells were seeded at a density of 5.0 x 104 cells/cm2 onto 24 well 
Transwell™ inserts with a 0.4µm pore. After cells grew into a confluent 
monolayer (48-72 hours), cells were treated with rTGFβ1, GW788388, SIS3, or 
dimethyl sulfoxide (DMSO) for 24 hours. Following treatment, inserts and 
chambers were washed with PBS and medium was replaced with phenol-red 
free media. 10kDa FITC-dextran (10 mg/ml; 10µl) was added to the upper well 
for one hour. Fluorescence (excitation 494nm; emission 520nm) was read in the 
upper and lower well and the permeability co-efficient determined using the 
following formula(136):  Pdextran = (RFUlower/RFUupper)(V)(1/t)(1/A), where RFU is 
the relative fluorescent units in the upper and lower wells, V is the volume of the 
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bottom well, t is the time that the FITC-dextran was allowed to diffuse and A is 
the total surface area of the monolayer (cm2). Permeability coefficients were 
normalized by setting basal cell monolayers to a value of 1 to minimize variability 
between trials. 
 
Immunofluorescence and immunohistochemistry 
For brain immunohistochemistry free-floating 30 µm sections were 
sectioned and put into 12-well plates containing PBS.  Sections were put in 0.5% 
hydrogen peroxide to quench endogenous peroxidase activity.  Brain sections 
were blocked in 5% goat serum prior to overnight incubation with specific 
antibodies against albumin.  Secondary antibodies and DAB peroxidase 
substrate were supplied from Vector Labs (Burlingame, CA).  Incubations and 
staining development were performed according to manufacturers protocols.  
The sections were viewed using an Olympus BX40 microscope with an Olympus 
DP25 imaging system (Olympus, Center Valley, PA).   
Free-floating immunofluorescence of the brain was performed on 30 µm 
sections.  Brains were initially blocked in 5% goat serum prior to overnight 
incubation with specific antibodies against albumin and SMI71.  
Immunocytochemistry in bEnd.3 cells was performed using the same methods 
with antibodies against MMP9 and Claudin-5.  Immunoreactivity was visualized 
using Dylight 488- or Cy3-conjugated secondary antibodies and counterstained 
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with DAPI.  Slides were viewed and imaged using a Leica TCS SP5-X inverted 
confocal microscope (Leica Microsystems, Buffalo Grove, IL). 
 
Real-time PCR 
RNA was extracted from bEnd.3 cells using the RNeasy mini kit from 
Qiagen (Valencia, CA) as per manufacturer’s protocols.  RNA content of isolated 
samples was calculated using a Thermo Scientific Nanodrop 2000 (Rockford, 
IL).  An iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA) was used to 
amplify 1 µg of RNA per reaction in a MyCyclerTM thermal cycler (Bio-Rad).  
cDNA was loaded onto 96-well plates with iTaq universal SYBR green supermix 
(Bio-Rad) along with commercially available primers designed against mouse 
Claudin-5, MMP9, and GAPDH. qPCR was performed using a Strategene 
Mx3005P qPCR system (Santa Clara, CA) and a ΔΔCT analysis was performed 
using basal bEnd.3 cells as controls(108, 109).  Data for all experiments are 
expressed as mean relative mRNA levels ± SEM (n=4). 
 
Immunoblotting 
Homogenization of bEnd.3 cells was accomplished by scraping cells in 
lysis buffer supplemented with 1% protease inhibitor cocktail.  Protein content in 
cell lysates from bEnd.3 cells was quantified using a BCA protein assay from 
Thermo Scientific.  SDS-PAGE gels were loaded with 10-20 µg of protein diluted 
in Laemmli buffer per lane.  Specific antibodies against Claudin-5, MMP9, and β-
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actin were used.  All imaging was performed on an Odyssey 9120 Infrared 
Imaging System (LI-COR, Lincoln, NE).  Data are expressed as fold change in 
fluorescent band intensity of target antibody divided by β-actin, which is used as 
a loading control.  The values of basal bEnd.3 cells were used as a baseline and 
set to a relative protein expression value of 1.  All treatment groups were 
changes of fluorescent band intensity of target antibody to β-actin relative to 
basal.  All band intensity quantifications were performed using ImageJ software 
(National Institutes of Health, Bethesda, MD).  Data for all experiments are 
expressed as mean relative protein ± SEM (n=4). 
 
Statistical analysis 
All statistical analyses were performed using Graphpad Prism software 
(Graphpad Software, La Jolla, CA).  Results were expressed as mean ± SEM.  
For data that passed normality tests, significance was established using the 
Student t test when differences between two groups were analyzed, and 
analysis of variance when differences between three or more groups were 
compared followed by the appropriate post hoc test.  If tests for normality failed, 
two groups were compared with a Mann-Whitney U test or a Kruskal-Wallis 
ranked analysis when more than two groups were analyzed.  Differences were 
considered significant when the p value was less than 0.05. 
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3.4.  Results 
 
The BBB is disrupted following AOM-induced liver failure 
 C57Bl/6 mice were treated with the hepatotoxin AOM for 6, 12, or 18 
hours prior to assessing Evan’s blue extravasation.  Mice that were treated for 
18 hours had significantly increased Evan’s blue dye present in their brains 
compared to those only perfused with the dye (figure 12A).  Interestingly, mice 
that underwent Evan’s blue extravasation assays at 6 and 12 hours post AOM 
injection had essentially no difference of Evan’s blue dye in the brain compared 
to untreated mice.  As Evan’s blue binds albumin, this gives support that the 
BBB is being disrupted in the later stages of ALF to a large enough degree to 
allow the passage of larger proteins through the barrier.  Representative pictures 
of untreated, 0-12 hours, and 18-hour brains support the findings from our 
absorbance measures (figure 12B).  Albumin immunofluorescence was 
performed in the cortex of vehicle mice and AOM mice and demonstrated that in 
vehicle mice there was only slight residual albumin staining in cerebral 
microvessels while in AOM mice albumin immunoreactivity is found diffusely 
spread throughout the tissue (figure 12C).  Together, these findings 
demonstrated that treatment with AOM, which induced liver failure, also caused 
disruption of the BBB at later stages that is demonstrated by increased albumin 
entry into the brain. 
 
	   57	  
Circulating TGFβ1 can disrupt the BBB 
 In an effort to understand the specific molecular effects of TGFβ1 on 
brain endothelial cells, confluent bEnd.3 monolayers were used as an in vitro 
model of the BBB.  Monolayers were treated with increasing doses of rTGFβ1 to 
determine if TGFβ1 could induce permeability of the monolayers.  At doses of 
1.0 ng/ml and 5.0 ng/ml of rTGFβ1 monolayers showed a significant increase in 
Fig. 12.  The BBB was disrupted in the later stages of HE.  (A) Evan’s blue permeability assay 
of AOM mice at indicated timepoints following AOM injection (n=4).  Permeability was 
measured by measuring absorbance of Evan’s blue dye (620 nM).  (B) Representative 
pictures of brains from mice that had no Evan’s blue extravasation (untreated), mice infused 
with Evan’s blue dye after AOM treatment from 0-12 hours, and mice infused with Evan’s blue 
dye 18 hours after AOM injection.  (C) Immunofluorescence in vehicle and AOM cortex for 
albumin (red) and DAPI (blue).  Data in the permeability assay is reported as mean ± SEM.  
*=p<0.05 compared to 0 hour mice.	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permeability to 10 kDa FITC-dextran (figure 13A).  To ensure that the effects 
being generated that lead to this permeabilization were entirely due to TGFβ1 
signal transduction, monolayers were treated with rTGFβ1 in combination with a 
TGFβRII antagonist, GW788388.  Treatment of bEnd.3 monolayers with 1.0 
ng/ml rTGFβ1 permeabilized the monolayers, but this effect was significantly 
reduced following treatment with 1 µM GW78838 (figure 13B).  This 
demonstrates that TGFβ1 is able to permeabilize monolayers of brain 
endothelial cells. 
 
 
 
Fig. 13.  Monolayers of brain endothelial cells were permeabilized by treatment with rTGFβ1.  
(A) Monolayers of bEnd.3 cells plated on transwells were treated with indicated doses of 
rTGFβ1 for 24 hours.  Permeability was assessed by 10-kDa FITC-dextran diffusion from the 
top chamber to the bottom chamber and subsequent reading of fluorescence from both top 
and bottom chamber (Excitation 494/Emission 520).  (B) Monolayers of brain endothelial cells 
were treated with rTGFβ1, the TGFβRII antagonist GW788388, or DMSO (vehicle for 
GW788388) for 24 hours.  Permeability was assessed by 10-kDa FITC-dextran diffusion from 
the top chamber to the bottom chamber and subsequent reading of fluorescence from both top 
and bottom chamber (Excitation 494/Emission 520).  Data in the monolayer assays are 
reported as mean ± SEM.  *=p<0.05 compared to basal bEnd.3 cells.	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Claudin-5 was downregulated by TGFβ1 in bEnd.3 cells 
 Due to the fact that TGFβ1 was able to permeabilize monolayers, the 
mechanism that generated this effect was investigated.   Assessment of the tight 
junction proteins Claudin-5, occludin, ZO-1, and ZO-2 was assessed following 
rTGFβ1 treatment.  There were no changes in occludin, ZO-1, and ZO-2 
expression when assessed by western blotting, RTPCR, or immunofluorescence 
(data not shown).  However, there were changes observed in Claudin-5.  
Treatment of bEnd.3 cells with rTGFβ1 above 1.0 ng/ml led to a significant 
suppression of Claudin-5 mRNA expression (figure 14A).  This effect translated 
into a reduction of Claudin-5 protein with significant suppression at doses of 0.5 
ng/ml rTGFβ1 and greater (figure 14B).  In order to determine if this translated to 
a functional disruption of the tight junction, immunofluorescence against Claudin-
5 was performed and demonstrated staining in the cell membrane of basal cells.  
However, when bEnd.3 cells were treated with rTGFβ1, Claudin-5 
immunostaining became increasingly cytoplasmic as doses increased, indicating 
a disruption of tight junctions (figure 14C).  These data demonstrated that 
TGFβ1 is able to both downregulate Claudin-5 and disrupt its localization to tight 
junctions in brain endothelial cells. 
 
MMP9 was also upregulated by TGFβ1 
In order to determine if the TGFβ1-induced disruption of brain endothelial 
cell permeability is also due to increased MMP9 activity, bEnd.3 cells were  
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treated with rTGFβ1 and assessed for MMP9 expression.  Treatment with  
rTGFβ1 led to a dose-dependent increase of MMP9 mRNA expression with 
treatments of 0.5 ng/ml rTGFβ1 and higher generating a significant increase 
(figure 15A).  To determine if this treatment led to increased protein levels of 
MMP9, immunofluorescence was performed and demonstrated a dose-
dependent increase in MMP9 immunostaining  (figure 15B).  Quantification of 
Fig. 14.  Claudin-5 expression was downregulated in bEnd.3 cells by TGFβ1.  (A) Claudin-5 
mRNA expression in bEnd.3 treated with increasing concentrations of rTGFβ1 as assessed by 
RTPCR.  (B) Claudin-5 protein expression in bEnd.3 cells treated with increasing 
concentrations of rTGFβ1 assessed by immunoblotting.   β-actin was used as a loading 
control and quantifications are normalized to basal bEnd.3 cells.  (C) Immunofluorescence 
investigating Claudin-5 (red) staining along tight junctions with DAPI (blue) used to stain 
nuclei.  The data from mRNA and protein analyses are reported as mean ± SEM.  *=p<0.05 
compared to basal bEnd.3 cells. 	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this immunofluorescence determined that doses of 1.0 ng/ml and 5.0 ng/ml of 
rTGFβ1 led to a significant increase of MMP9 immunoreactivity (figure 15C).  
These data demonstrate that TGFβ1 may generate its effects on permeability 
through upregulation of MMP9.   
Fig. 15.  MMP9 was upregulated by TGFβ1 in bEnd.3 cells.  (A) MMP9 mRNA expression in 
bEnd.3 cells following treatment with rTGFβ1 as assessed by RTPCR.  (B) Coverslips of 
bEnd.3 cells were stained for MMP9 (red) and DAPI (blue) as a nuclear stain following 
treatment with increasing doses of rTGFβ1.  (C) Quantification of MMP9 
immunofluorescence for bEnd.3 cells grown on coverslips following treatment with rTGFβ1.  
The data from mRNA and immunofluorescence quantification analyses are reported as 
mean ± SEM.  *=p<0.05 compared to basal bEnd.3 cells.	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Modulations of Claudin5 and MMP9 via TGFβ1 were dependent on SMAD3 
  To determine if TGFβ1 was exerting its effects through a SMAD3-
dependent mechanism, bEnd.3 cells were treated with rTGFβ1 and the SMAD3 
antagonist SIS3.  Treatment of monolayers with TGFβ1 and SIS3 was able to 
alleviate the permeability caused by TGFβ1 (figure 16A).  Associated with this, 
treatment with both TGFβ1 and SIS3 was also able to rescue the 
downregulation of Claudin-5 mRNA (figure 16B) and protein (figure 16C) 
compared to TGFβ1 treatment by itself.  In order to determine if disruption of 
cellular localization of Claudin-5 was dependent upon SMAD3, coverslips of 
bEnd.3 cells were treated with rTGFβ1 and SIS3.  Treatment of bEnd.3 cells 
with SIS3 was able to somewhat restore the localization of Claudin-5 to the cell 
membrane (figure 16D). 
A SMAD3-dependent mechanism could potentially play a role in the 
upregulation of MMP9 by TGFβ1 as well.  Treatment of bEnd.3 cells with TGFβ1 
and SIS3 significantly reduced MMP9 mRNA expression back to near the levels 
of basal cells (figure 17A).  Associated with this, SIS3 treatment of TGFβ1 
treated bEnd.3 coverslips was able to reduce MMP9 immunofluorescence to 
near basal levels (figure 17B).  Quantification of MMP9 immunofluorescence 
determined that treatment with SIS3 was able to significantly reduce MMP9 
immunoreactivity in bEnd.3 cells to near basal levels (figure 17C).  Together, 
these findings demonstrate that downregulation of Claudin-5 and upregulation of 
MMP9 via TGFβ1 in brain endothelial cells is dependent upon SMAD3. 
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Fig. 16.  Claudin-5 downregulation via TGFβ1 occured through a SMAD3-dependent 
mechanism.  (A) Monolayers of bEnd.3 cells were treated with rTGFβ1, the SMAD3 inhibitor 
SIS3, or SIS3 vehicle (DMSO) for 24 hours.  Permeability was assessed by 10-kDa FITC-
dextran diffusion from the top chamber to the bottom chamber and subsequent reading of 
fluorescence from both top and bottom chamber (Excitation 494/Emission 520).  (B) Claudin-5 
mRNA expression in bEnd.3 cells treated with rTGFβ1, the SMAD3 inhibitor SIS3, or SIS3 
vehicle (DMSO) for 24 hours.  (C) Claudin-5 protein in bEnd.3 cells treated with rTGFβ1, the 
SMAD3 inhibitor SIS3, or SIS3 vehicle (DMSO) for 24 hours as assessed by immunoblotting.  
β-actin is used as a loading control and quantifications are normalized to basal bEnd.3 cells.  
(D) Claudin-5 (red) immunofluorescence in bEnd.3 cells treated with rTGFβ1, the SMAD3 
inhibitor SIS3, or SIS3 vehicle (DMSO) for 24 hours.  DAPI (blue) was used as a nuclear stain.  
The data from mRNA and immunoblot analyses are reported as mean ± SEM.  *=p<0.05 
compared to basal bEnd.3 cells.	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Fig. 17.  SMAD3 was required for upregulation of MMP9 by TGFβ1.  (A) Relative MMP9 
mRNA expression in bEnd.3 cells treated with rTGFβ1, the SMAD3 inhibitor SIS3, or 
SIS3 vehicle (DMSO) for 24 hours.  (B) bEnd.3 cells were grown on coverslips and 
treated with rTGFβ1, the SMAD3 inhibitor SIS3, or SIS3 vehicle (DMSO) for 24 hours.  
Immunofluorescence against MMP9 (red) and DAPI (blue) were performed.  (C) 
Quantification of MMP9 immunofluorescence in bEnd.3 cells following treatment with 
rTGFβ1.  The data from mRNA and immunofluorescence quantification analyses are 
reported as mean ± SEM.  *=p<0.05 compared to basal bEnd.3 cells.	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In vivo neutralization of TGFβ1 reduced BBB permeability following liver failure 
 Evan’s blue extravasation assay was performed in mice treated with AOM 
and/or neutralizing antibodies against TGFβ for 18 hours.  Mice injected with 
AOM demonstrated a significant increase in Evan’s blue dye in their brain and 
this increase was significantly reduced if the mice were pretreated with 
neutralizing antibodies against TGFβ (figure 18A).  Representative pictures of 
the brains of mice treated with AOM and/or neutralizing antibodies against TGFβ 
support these results (figure 18B).  To show this effect to a greater degree, 
immunohistochemistry was performed against albumin in the brains of mice 
treated with AOM and neutralizing antibodies against TGFβ.  This 
immunohistochemistry displayed a significant elevation of albumin in the cortex 
of AOM mice that was reduced in mice treated with neutralizing antibodies 
against TGFβ (figure 18C).  In order to visualize the brain microvascular 
endothelial cells, immunofluorescence staining was performed for the 
endothelial cell marker SMI71.  AOM-treated mice showed discontinuous 
staining for SMI71 while mice pretreated with neutralizing antibodies against 
TGFβ displayed continuous staining which is similar to vehicle-treated mice 
(figure 18D).  These data demonstrated that inhibiting circulating TGFβ1 activity 
in vivo was able to restore BBB function following ALF. 
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Fig. 18.  Treatment of AOM mice with neutralizing antibodies against TGFβ reduced BBB 
dysfunction.  (A) Evan’s blue permeability assay of mice treated with AOM or with 
neutralizing antibodies against TGFβ for 18 hours (n=4).  Permeability was measured by 
measuring absorbance of Evan’s blue dye (620 nM).   (B) Representative images of Evan’s 
blue extravasation in vehicle, AOM, AOM + antiTGFβ, and antiTGFβ mice.  (C) 
Immunohistochemistry against albumin in the cortex of vehicle, AOM, AOM + antiTGFβ, and 
antiTGFβ mice.  (D) Immunofluorescence staining for the endothelial cell marker SMI71 
(red) with DAPI (blue) used as a nuclear stain in the cortex of vehicle, AOM, AOM + 
antiTGFβ, and antiTGFβ mice. Data in the permeability assay are reported as mean ± SEM.  
*=p<0.05 compared to vehicle treated mice.	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3.5.  Discussion 
 
 This manuscript reports the findings that 18 hours following AOM injection 
the BBB is significantly disrupted as measured by Evan’s blue extravasation.  
Investigation into the molecular mechanisms that drive this effect determined 
that brain endothelial cells have reduced Claudin-5 expression and increased 
MMP9 expression following treatment with rTGFβ1.  The suppression of 
Claudin-5 and increased MMP9 expression was found to be dependent upon 
SMAD3 signaling as treatment with the SMAD3 inhibitor SIS3 was able to 
reverse the effects of rTGFβ1 treatment.  Finally, inhibition of circulating TGFβ1 
in AOM-treated mice by injection of neutralizing antibodies was able to reduce 
albumin infiltration in the brain, reduce microvessel disruption and significantly 
reduce BBB permeability compared to mice treated with AOM alone.  A working 
model of our findings is presented in figure 19. 
This study demonstrates that the AOM model of HE generates a 
significant disruption of the BBB as measured by the presence of Evan’s blue 
dye in the cerebral cortices of AOM-treated mice.  Interestingly, this only 
occured at later stages of HE when severe neurological decline was present 
(ataxia and minor reflex deficits are typically observed around twelve hours in 
this model).  Other researchers have performed Evan’s blue extravasation using 
a lower dose of AOM (50 mg/kg) and have shown similar findings(132).  
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Fig. 19.  Working model of TGFβ-induced permeability of BBB.  Following liver insult, 
TGFβ1 is released from the liver into the circulation.  This generates two separate effects.  
One is a direct effect on endothelial cells by downregulating Claudin-5 and subsequent 
disruption of tight junctions.  The other effect of TGFβ1 is the upregulation of MMP9 in 
endothelial cells with subsequent release into the circulation and digestion of Claudin-5.  
Together these effects allow signaling proteins like TGFβ1 and toxins to pass through the 
BBB and enter into the brain to exacerbate HE pathology.	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Furthermore, rats treated with D-galactosamine to induce ALF show significant 
increase of Evan’s blue extravasation at coma(137).  These findings mirror the 
more recent reports of vasogenic edema that have been reported in clinical 
studies in both acute and chronic liver failure(138, 139).  That being said, the 
findings from our current study do support the finding that BBB permeability is 
only seen in later stages of HE.  This in itself does not answer what pathological 
processes could be involved in the earlier stages of HE progression and remain 
an area that needs to be further studied to better understand this disease. 
Previous research into the effects of tight junction proteins following ALF 
has been conflicting.  One group of researchers found that AOM-treated mice 
have a disruption of occludin, Claudin-5, zona occludens-1, and zona occludens-
2 as assessed by western blot(124).  However, other researchers have used the 
AOM model and observed no changes in immunoblot tight junction protein 
expression(140).  Our findings in the treatment of bEnd.3 cells with rTGFβ1 
demonstrated a downregulation of the tight junction protein Claudin-5 as well as 
translocation of the protein from the cell membrane to the cytosol.  Claudin-5 
downregulation has been shown to lead to increased BBB permeability following 
hypoxia(141), focal cerebral cooling(142), and ischemia reperfusion injury(143).  
Also, other studies have found that TGFβ1 can lead to the direct downregulation 
of Claudin-5(144).  Interestingly, we found that rTGFβ1 treatment led to no 
significant changes in occludin, zona occludens-1, or zona occuldens-2.  Thus, 
our findings support the concept that circulating TGFβ1 could be driving the BBB 
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permeability that we observed in vivo through downregulation of Claudin-5.  This 
does not discount involvement of occludin or zona occuldens in BBB 
permeability following ALF and studies investigating these signaling proteins and 
the signaling factors that interact with them are still necessary.     
 This study also found that MMP9 expression was increased in bEnd.3 
cells following treatment with rTGFβ1.  TGFβ1 has been shown to lead to 
increased expression of MMP9 in corneal epithelial cells(145) and in podocytes 
(146).  MMP9 plays many roles in dysregulation of the BBB as it has the 
capability to degrade Claudin-5, occludin, ZO-1, and ZO-2(130).  In models of 
AOM-induced ALF, MMP9 has been demonstrated to be upregulated in the 
serum while its physiological inhibitor TIMP1 is downregulated(132, 137).  This 
upregulation of MMP9 has been shown to disrupt tight junctions and inhibiting 
MMP9 can reduce BBB permeability(124).  Interestingly, it has also been shown 
that ammonia treatment of rat brain microvascular endothelial cells by itself is 
able to induce MMP9 expression(147).  Thus, it is conceivable that TGFβ1 could 
potentially be acting synergistically with ammonia to induce MMP9 expression 
and further drive BBB permeability. 
TGFβ1 is able to transduce its signaling via activation of its receptor and 
subsequent phosphorylation of SMAD proteins.  TGFβ1 signaling can be 
transduced via SMAD2 or through SMAD3(148).  We determined that SMAD3 
was generating the majority of the effects that we were seeing both in vivo and 
in vitro due to the fact that treatment with SIS3 was able to reverse most of the 
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effects of TGFβ1.  Interestingly, other studies have inhibited TGFβ receptor 
kinase activity, which reduced SMAD3 activity and was able to elevate Claudin-5 
expression(149).  In addition, human meningeal cells treated with a SMAD3 
inhibitor were able to attenuate TGFβ1-dependent MMP9 upregulation(150).  
Thus, there is strong evidence that supports dysregulation of both Claudin-5 and 
MMP9 by TGFβ1 via a SMAD3-dependent mechanism and these effects could 
be driving some of the effects on BBB permeability observed here.  However, 
this does not exclude the possibility that TGFβ1/SMAD3 signaling could be 
having other effects on these cells as well, such as affecting junctional adhesion 
molecules or proteins of the adherens junction, which could also disrupt 
permeability of the BBB.  Also of note is that our studies specifically investigated 
only the effects of SMAD3 activity modulation, and due to this, we cannot 
discount that there might be some involvement of SMAD2 in the effects that 
were observed. 
 BBB manipulations in vivo via sequestration of circulating TGFβ1 
demonstrated that TGFβ1 plays a significant role in promoting permeability of 
the BBB in this model of ALF.  It is possible that some of these effects could be 
due to downstream TGFβ1 signaling in brain endothelial cells.  One of TGFβ1 
downstream targets is the activation of PI3K/Akt signaling(151) which has been 
demonstrated to promote vascular permeability in cancer models(152, 153).  
Also, this pathway has been shown to induce BBB permeability following focal 
cerebral ischemia(154), HIV-induced BBB disruption(155), and traumatic brain 
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injury(156).  Outside of this pathway, hedgehog signaling has been shown to be 
protective in experimental autoimmune encephalomyelitis, a mouse model of 
multiple sclerosis, by promoting BBB integrity(66).  Also, treatment of mice with 
polydatin, which elevates Gli1, has been shown to restore BBB function 
following ischemic insult(95).  These findings support that inhibiting TGFβ1 could 
promote BBB integrity via suppression of vascular permeability pathway 
signaling as well as inducing factors to promote BBB vascular integrity.  
However, research into the specific signaling pathways that are dysregulated by 
TGFβ1 specifically in brain endothelial cells are still warranted and are currently 
ongoing in the laboratory.  
 Together, our findings support that TGFβ1 is driving BBB permeability via 
downregulation of Claudin-5 and upregulation of MMP9 and that these effects 
are dependent upon SMAD3.  These results support that manipulations of 
TGFβ1 or therapies to target SMAD3 may be potential therapeutic targets to 
treat patients with ALF who have the potential to develop HE. 
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4.  TGFβ1 ACTIVATES MICROGLIA DURING HEPATIC ENCEPHALOPATHY 
 
4.1.  Overview 
 
HE that arises following liver failure has been associated with increases in 
neuroinflammation.  CCL3 is a proinflammatory chemokine that leads to 
activation of microglia through activation of CCR1-mediated signaling.  The aims 
of this study were to assess CCL3/CCR1 signaling during HE and if TGFβ1 is a 
primary inducer of this signaling.  Microglia depletion was accomplished through 
ICV injection of clodronate liposomes.  Treatment with neutralizing antibodies 
against TGFβ was used to inhibit circulating TGFβ1.  CCL3 knockout mice were 
employed to determine its role in HE pathogenesis.  Neural expression of CCL3, 
CCR1, NF-κB, and ERK1/2 were assessed.  CCL3 and CCR1 protein 
expression was assessed in patients with HE, in cirrhotic patients w/o HE, or 
age-matched controls.  Microglia were activated during HE and their depletion 
via clodronate liposomes reduced neurological decline. CCR1 activity was found 
to be elevated without increased CCR1 expression in HE mice.  Systemic 
reduction of TGFβ1 reduced CCL3/CCR1 signaling in AOM mice.  CCL3 
knockout did not affect neurological decline associated with HE.  Microglia 
activation was pathological during HE and was dependent on circulating TGFβ1.  
However, the CCL3/CCR1 signaling axis may not be the primary signaling 
pathway that activates microglia during HE. 
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4.2.  Introduction 
 
 Chemokines are chemoattractant cytokines that facilitate immune cell 
differentiation, regulate inflammation, and promote leukocyte trafficking(157).  
Besides these functions, chemokines have the ability to regulate free radicals, 
nitric oxide, cytokines, and matrix metalloproteinases as well as control 
apoptosis, cell cycle regulation and angiogenesis(158).  In the brain, 
chemokines facilitate the recruitment and activation of microglia(159).  In 
regards to HE, it has been demonstrated that microglia are activated in a model 
of ammonia neurotoxicity in rats treated with an intraperitoneal injection of 
ammonium acetate(57), during hepatic devascularization in rats(54), and in the 
AOM model of liver failure(160).  However, there are few studies that have 
studied the influence of chemokines during HE with no reports investigating 
chemokines in toxin-induced liver failure with subsequent HE. 
 Chemokine ligand 3 (CCL3), or macrophage inflammatory protein-1α, is a 
proinflammatory chemokine that transduces its signaling via chemokine receptor 
1 (CCR1)(161).  In the liver, CCL3 expression, as well as other cytokines, have 
been found to be elevated following chronic injury using BDL or CCl4 models of 
liver damage(162).  In the brain, elevated CCL3 expression has been shown in a 
mouse model of the lysosomal storage disorder Goucher’s disease, which has 
been classified with microgliosis(163).  Also excitotoxic injury with kainic acid 
was found to lead to elevations of CCL3, which correlated with microglia 
	   75	  
recruitment(164).  As models of HE have portrayed microglia recruitment to be a 
part of the pathology present, it is conceivable that CCL3/CCR1 signaling may 
be playing a role in facilitating microglial activation during HE, although definitive 
evidence of this is lacking.   
 TGFβ1 is a signaling factor involved in many pathological inflammatory 
processes.  However, its role in inflammation in the brain has not been fully 
elucidated.  Previous research in our laboratory has demonstrated the inhibition 
of circulating TGFβ1 during HE reduced neurological decline associated with the 
disorder.  Also, studies have found that during experimental autoimmune 
encephalomyelitis, a mouse model of multiple sclerosis, that TGFβ1 helps 
sustain neuroinflammation(120).  This effect could be a result of TGFβ1 having 
the ability to upregulate chemokine receptor expression, in particular 
CCR1(165).   
 Thus, the overall hypothesis of this study is that microglia are activated 
during HE via CCL3/CCR1 signaling and that TGFβ1 is exacerbating 
neuroinflammation by enhancing the activity of this signaling pathway.  Gaining 
understanding into the inflammatory processes that occurs during HE could 
eventually help lead to the development of therapeutics to help treat patients 
with this disease. 
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4.3.  Materials and Methods 
 
Materials 
Antibodies against CCR1, CCL3, p84 and GAPDH were purchased from 
Genetex (Irvine, CA).  Antibodies against NeuN were purchased from Millipore 
(Billerica, MA).  Antibodies against NF-κB p65 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Neutralizing antibodies against TGFβ (anti 
TGFβ) were purchased from R&D systems (Minneapolis, MN).  All RTPCR 
primers were purchased from SA Biosciences (Frederick, MD).  All other 
chemicals were purchased from Sigma-Aldrich (St. Louis MO) unless otherwise 
noted, and were of the highest grade available.     
 
Experimental animals and hepatic encephalopathy model 
Mouse in vivo experiments were performed using male C57Bl/6 mice (25-
30 g; Charles River Laboratories, Wilmington, MA).  Mice were allowed free 
access to drinking water and standard mouse chow and were housed in 
constant temperature, humidity, and 12 hour light-dark cycling.  Mice received a 
single intraperitoneal injection of 100 mg/kg AOM to induce ALF and HE.  
Control animals were injected with an equal volume of saline.  After injection, 
mice were placed on heating pads set to 37°C and under heating lamps to 
ensure they maintained normal body temperature.  Also, mice were supplied 
with hydrogel and rodent chow on their cage floor to ensure they had easy 
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access to food and hydration.  After 12 hours and every 4 hours following, mice 
were injected subcutaneously with 500 µl of a 5% dextrose solution to ensure 
that they did not become hypoglycemic.  Mice were removed from the study if 
they underwent a 20% weight loss.   
Following AOM injection, mice were monitored every two hours (starting 
at eight hours post AOM injection) for body temperature, weight, and 
neurological decline.  Neurological decline was assessed by measuring the 
pinna reflex, corneal reflex, tail flexion, escape response, righting reflex, and 
ataxia.  The pinna reflex was assessed by touching the external auditory meatus 
with a cotton applicator and observing ear retraction or head movement.  The 
corneal reflex was measured by touching the cornea with a cotton applicator and 
measuring the blink response.  Tail flexion was measured via tail pinch with 
forceps and assessing tail flexion.  Escape response was measured by tail pinch 
by forceps and a subsequent movement of mice away from stimuli.   The righting 
reflex was assessed by placing the mice on their back and measuring the time 
for them to right themselves.  Assessment of ataxia was performed by observing 
movement activity when the mice were placed on the cage wire bar lid. Mice in 
all groups were euthanized at indicated timepoints or were allowed to progress 
to coma (loss of both righting and corneal reflexes). 
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Genetic and pharmacological manipulations 
 Suppression of circulating TGFβ1 activity was accomplished through 
injection of TGFβ neutralizing antibodies.  This required a single intraperitoneal 
injection at 1 mg/kg 2 hours prior to AOM injection. Clodronate liposomes or 
control liposomes were intracerebroventricular (ICV) injected into the lateral 
ventricle (10 µl of a 100 µg/g solution) to deplete microglia in the brain.  The 
liposomes were obtained from Dr. Nico van Rooijen (Harleem, The 
Netherlands).  CCL3 gene expression was ablated in vehicle and AOM mice 
through the use of commercially available CCL3 knockout mice (The Jackson 
Laboratory, Stock # 002687, Bar Harbor, ME).  
 
Human samples 
Brain tissue from patients who had HE following liver cirrhosis, cirrhotic 
patients without HE or aged-matched controls without liver disease were 
supplied through the New South Wales Tissue Resource Centre at the 
University of Sydney.  Immunohistochemistry was performed against human 
CCL3 or CCR1 on these tissues as described below. 
 
Free floating immunofluorescence 
Free-floating immunofluorescence of the brain was performed on 30 µm 
sections.  Brains were initially blocked in 5% goat serum prior to overnight 
incubation with specific antibodies against CCR1, CCL3, IBA1 and/or NeuN. 
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Immunoreactivity was visualized using Dylight 488- or Cy3-conjugated 
secondary antibodies and counterstained with DAPI following mounting onto 
slides.  Mounted brain sections were viewed and imaged using a Leica TCS 
SP5-X inverted confocal microscope (Leica Microsystems, Buffalo Grove, IL). 
 
Real-time PCR 
RNA was extracted from brain tissue using the RNeasy mini kit from 
Qiagen (Valencia, CA) as per manufacturer’s protocols.  RNA content of isolated 
samples was calculated using a Thermo Scientific Nanodrop 2000 (Rockford, 
IL).  An iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA) was used to 
amplify 1 µg of RNA per reaction in a MyCyclerTM thermal cycler (Bio-Rad).  
cDNA was loaded onto 96-well plates with iTaq universal SYBR green supermix 
(Bio-Rad) along with commercially available primers designed against mouse 
CCL3 and GAPDH. qPCR was performed using a Strategene Mx3005P qPCR 
system (Santa Clara, CA) and a ΔΔCT analysis was performed using vehicle 
tissue as controls(108, 109).  Data for all experiments are expressed as mean 
relative mRNA levels ± SEM (n=4). 
 
Immunoblotting 
Homogenization of cortex and cerebellum was accomplished by 
mechanical disruption in cell lysis buffer supplemented with 1% protease 
inhibitor cocktail.  Tissue fractionations were accomplished using a 
	   80	  
ProteoExtractTM Subcellular Proteome Extraction Kit (Calbiochem, Billerica, 
MD).  Protein content in lysates was quantified using a BCA protein assay from 
Thermo Scientific.  SDS-PAGE gels were loaded with 10-20 µg of protein diluted 
in Laemlli buffer per lane.  Specific antibodies against CCL3, CCR1, NF-κB, p84, 
pERK1/2, tERK1/2, GAPDH and β-actin were used.  All imaging was performed 
on an Odyssey 9120 Infrared Imaging System (LI-COR, Lincoln, NE).  Data are 
expressed as fold change in fluorescent band intensity of target antibody divided 
by β-actin, which was used as a loading control.  The values of control cortex 
were used as a baseline and set to a relative protein expression value of 1.  All 
treatment groups were plotted as changes of fluorescent band intensity of target 
antibody to β-actin relative to basal.  All band intensity quantifications were 
performed using ImageJ software (National Institutes of Health, Bethesda, MD).  
Data for all experiments are expressed as mean relative protein ± SEM (n=4). 
 
Genotyping 
 DNA was isolated from brain tissue from CCL3 knockout and wild-type 
mice using a Qiagen DNeasy Blood & Tissue Kit.  DNA was quantified in the 
samples using a Thermo Scientific Nanodrop 2000.  Standard PCR was 
performed using the protocol supplied from The Jackson Laboratory using 250 
ng of DNA per sample and the reaction was run in a Bio-Rad MyCyclerTM 
thermal cycler.  Wild-type primers used 5’ à 3’ were ATG AAG GTC TCC ACC 
ACT GC and AGT CAA CGA TGA ATT GGC G.  CCL3 knockout primers used 
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5’ à 3’ were CTT CGG TGG AGA GGC TAT TC and AGG TGA GAT GAC AGG 
AGA TC.  Amplified DNA was loaded into a 2% agarose gel and electrophoresis 
was performed.  Gels were stained for 10 minutes with ethidium bromide 
(Amresco, Solon, OH) and imaged in a FischerBiotechTM ultraviolet 
transilluminator (Fisher Scientific, Pittsburg, PA).   
 
Statistical analysis 
All statistical analyses were performed using Graphpad Prism software 
(Graphpad Software, La Jolla, CA).  Results were expressed as mean ± SEM.  
For data that passed normality tests, significance was established using the 
Student t test when differences between two groups were analyzed, and 
analysis of variance when differences between three or more groups were 
compared followed by the appropriate post hoc test.  If tests for normality failed, 
two groups were compared with a Mann-Whitney U test or a Kruskal-Wallis 
ranked analysis when more than two groups were analyzed.  Differences were 
considered significant when the p value was less than 0.05. 
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4.4.  Results 
 
Microglia activation during HE contributed to pathology 
 Microglia, as imaged with IBA1 immunostaining, demonstrated a shift 
from a quiescent ramified morphology to a more amoeboid phenotype in the 
cortex of AOM mice (figure 20A).  Representations of field IBA1 staining in the 
cortex of vehicle and AOM-treated mice demonstrated increased staining in 
AOM cortex compared to vehicle, which was indicative of microgliosis being 
present following the development of HE (figure 20B).  Quantification of this 
staining demonstrated that there was a significant increase in IBA1 staining in 
the cortex and cerebellum of AOM mice, demonstrating that microgliosis was 
present in the brain following development of HE (figure 20C).  In order to see if 
this microglia activation was driving the pathogenesis of HE, clodronate 
liposomes were injected ICV into the lateral ventricle.  This depletion of microglia 
was found to be protective as animals injected with clodronate liposomes took 
significantly longer to reach coma than mice injected with PBS liposomes (figure 
20D). 
 
CCL3 was upregulated in cortical neurons following development of HE 
The cortex of AOM mice displayed a significant elevation of CCL3 mRNA 
compared to vehicle-treated mice (figure 21A).  Investigation into whether this 
change in gene expression translated to a subsequent increase of CCL3 protein 
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found that AOM mice demonstrated a significant increase of cortical CCL3 
protein compared to vehicle-treated mice (figure 21B).  Cortical neurons were 
found to predominantly express CCL3 protein due to the co-localization of CCL3 
with the neuronal marker NeuN (figure 21C).  In order to ascertain whether these 
observations that were present in AOM mice are also found in cases of clinical 
HE, immunohistochemistry was performed against CCL3 in cortical tissue from 
Fig. 20.  Microglia activation during HE exacerbated pathology.  (A) Immunofluorescence 
for IBA1 in the cortex of mice treated with AOM or vehicle.  (B) Representative field views 
of IBA1 immunofluorescence in AOM or vehicle-injected cortices.  (C) Quantifications of 
IBA1 field fluorescence in both the cortex and cerebellum of vehicle and AOM mice.  (D) 
Time to coma in hours for AOM mice following ICV injection of PBS or clodronate 
liposomes. The data from immunofluorescence quantification and time to coma analyses 
are reported as mean ± SEM.  *=p<0.05 compared to vehicle or PBS liposomes. 
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Fig. 21. CCL3 was upregulated during HE in both mice and patients.  (A) Cortical CCL3 
mRNA was assessed in vehicle and AOM-treated mice via RTPCR.  (B) Immunoblots 
against CCL3 in the cortex of vehicle and AOM mice.  (C) Immunofluorescence for CCL3 
(red) and NeuN (green) in the cortex of vehicle mice.  (D) Representative CCL3 
immunohistochemistry in the cortex of patients with HE, cirrhotics w/o HE, or age-matched 
controls.  (E) Quantification of CCL3 immunohistochemical staining in the cortex of 
patients with HE, cirrhotics w/o HE, or age-matched controls.  The data from RTPCR, 
immunoblot, and immunostaining quantification analyses are reported as mean ± SEM.  
*=p<0.05 compared to vehicle or control patient cortex. 
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HE patients, cirrhotic patients without HE, and appropriate controls (figure 21D).  
Quantifications of these stains demonstrated that HE patients had significantly 
increased CCL3 protein compared to control patients or to cirrhotic patients 
without HE (figure 21E). 
 
CCR1 activity, but not expression, was elevated during HE 
 Both vehicle and AOM mice had no significant differences in protein 
expression of CCR1 (figure 22A).  However, there was evidence of increased 
CCR1 activity by measuring downstream signaling.  Measurements of 
phosphorylated ERK1/2 in the cortex at various stages of neurological decline 
after AOM injection demonstrated increased phosphorylation with the greatest 
increase being early in disease progression (figure 22B).  In addition to this, 
fractionated cortex homogenates demonstrated increased NF-κB in the nuclear 
fraction of AOM mice compared to vehicle-treated mice (figure 22C).  Due to 
previous publications finding CCR1 expression in microglia(166-168), we wanted 
to validate that CCR1 was not present in cortical neurons or astrocytes.  
Immunofluorescence was performed and we found no colocalization of CCR1 
expression with the neuronal marker NeuN or the astrocyte marker GFAP (figure 
22D).  To ensure that patients with HE had no significant changes in CCR1 
expression, immunohistochemistry was performed in HE patients, cirrhotic 
patients without HE, and appropriate age-matched controls (figure 22E).  
Quantification of this data determined that there were no significant  
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Fig. 22.  CCR1 downstream activity was elevated during HE.  (A) CCR1 protein expression in 
vehicle and AOM cortex.  (B) Phosphorylation of ERK1/2 was assessed in vehicle and AOM 
cortex across all stages of neurological decline.  (C) NF-κB immunoblots in cytoplasmic and 
nuclear fractions from vehicle and AOM cortex.  (D) CCR1 (red), NeuN (green), or GFAP 
(green) immunofluorescence in the cortex of vehicle mice with DAPI (blue) used as a nuclear 
stain.  (E) CCR1 immunohistochemistry in HE patients, cirrhotic patients w/o HE, or age-
matched controls.  (F) Relative CCR1 staining intensity of the three clinical groups.  The data 
from immunostaining quantification analyses are reported as mean ± SEM.	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differences in CCR1 protein in the cortex of these three clinical populations 
(figure 22F). 
 
TGFβ1 drives CCL3 upregulation and CCR1 receptor activity 
 As we have previously demonstrated that TGFβ1 is upregulated following 
AOM administration both systemically and centrally, we wanted to see if this 
protein was driving some of the effects that we were observing with chemokines.  
The upregulation of CCL3 protein observed following AOM administration in the 
cortex was significantly reduced following treatment with neutralizing antibodies 
against TGFβ (figure 23A).  Furthermore, the nuclear translocation of NF-κB that 
was present in the cortex of AOM mice was significantly reduced as well (figure 
23B).  To see if these signaling events had any effects on microglia activation 
and microgliosis, IBA1 staining was performed in the cortex and cerebellum.  In 
the cortex of AOM mice, microglia adopted a more amoeboid shape, which was 
not observed as readily in mice treated with neutralizing antibodies against 
TGFβ (figure 23C).  Quantification of IBA1 staining in the cortex of mice treated 
with AOM and/or neutralizing antibodies against TGFβ demonstrated that AOM 
mice had a significant increase of microgliosis and this effect was not found in 
mice co-treated with AOM and neutralizing antibodies against TGFβ (figure 
23D).  These same observations also held true in the cerebellum (figure 23E).  
Thus, there is evidence that TGFβ1 may be driving microglia activation through 
CCL3/CCR1 signaling. 
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Fig. 23.  Treatment with neutralizing antibodies against TGFβ reduced CCL3/CCR1 activity 
and microglia activity.  (A) Western blots for CCL3 in vehicle, AOM, AOM + anti TGFβ, and 
anti TGFβ cortex.  (B) NF-κB protein in fractionated cortex of vehicle, AOM, AOM + anti 
TGFβ, and anti TGFβ mice.  (C) IBA1 immunofluorescence in vehicle, AOM, AOM + anti 
TGFβ, and anti TGFβ cortex.  (D) Quantification of IBA1 immunofluorescence in vehicle, 
AOM, AOM + anti TGFβ, and anti TGFβ cortex.  (E) Quantification of IBA1 
immunofluorescence of vehicle, AOM, AOM + anti TGFβ, and anti TGFβ cerebellum.  The 
data from immunoblot and immunofluorescence quantification analyses are reported as 
mean ± SEM.  *=p<0.05 compared to vehicle cortex or cerebellum. 
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CCL3 knockout does not protect from neurological decline 
 The use of a commercially available knockout mouse for CCL3 was 
employed to investigate the contribution of this chemokine to the pathogenesis 
of HE.  CCL3 knockout and wild-type mice were injected with AOM and there 
were no significant differences in time to coma between these two groups (figure 
24A).  As this effect was surprising, we validated that these mice did have a 
genetic manipulation that led to the functional suppression of CCL3 protein.  
CCL3 PCR was performed and demonstrated that the CCL3 knockout mice did 
in fact have a genetic manipulation as described by the manufacturer (figure 
24B).  We performed CCL3 immunofluorescence in the brain to validate that 
CCL3 protein expression was reduced in the knockouts.  Vehicle and AOM-
treated wild-type mice displayed CCL3 protein expression, but there was no 
expression in the CCL3 knockout mice (figure 24C). 
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Fig. 24.  Knockout of CCL3 did not reduce HE pathogenesis.  (A) Time to coma in wild-
type and CCL3 knock out (KO) mice.  (B) Representative PCR gel for the CCL3 gene 
(668 base pairs for the normal gene compared to 280 base pairs in the mutant gene) in 
the knockout animals compared to wild-type.  (C) Immunofluorescence for CCL3 (red) in 
the wild-type and knockouts of both vehicle and AOM mice with DAPI (blue) used as a 
nuclear stain.  The data from the time to coma analysis is reported as mean ± SEM. 
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4.5.  Discussion 
 
 The following study identified that microglia become activated, undergo 
microgliosis, and generate pathology in AOM-treated mice.  Associated with this 
was an increase of CCL3 expression and CCR1 activity in the cortex of both 
AOM mice and patients who had HE.  Therapeutic strategies to reduce 
circulating levels of TGFβ1 were demonstrated to reduce CCL3 expression and 
CCR1 activity in AOM mice.  However, CCL3 knockout did not generate a 
significant change in pathology demonstrating that targeting of total CCL3 
signaling may not be the appropriate therapeutic target for management of HE.  
A working model of our findings is displayed below (figure 25). 
 Our initial finding was that microglia were activated and microgliosis was 
occurring during AOM-induced HE.  Inhibition of microglia activation using 
minocycline in rats whom had undergone hepatic devascularization to cause 
ALF was found to have reduced oxidative stress and a reduction in inflammatory 
cytokine expression(54, 58).  Also, knockouts of the receptors for IL-1 or TNF 
were found to reduce the onset of encephalopathy and reduce brain edema in 
AOM-treated mice(55).  The use of hypothermia, which reduces inflammation 
and oxidative stress, has been shown to be protective during HE in rats with 
ALF(169) and can be used to improve clinical patient outcomes until 
transplantation is available(20, 38).  Due to the fact that others have identified 
microgliosis and microglia activation during HE and that  
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inflammation is highly correlated with HE pathogenesis, there is support that 
microglia were playing a prominent role in driving the pathology present during 
HE. 
 There have been a number of studies assessing the role of CCL3 in liver 
damage and fibrosis following injury.  The use of a concanavalin A-induced 
hepatitis model of liver damage in mice demonstrates that CCL3 promotes 
Fig. 25.  Working model of TGFβ induced CCL3/CCR1 signaling following ALF.  TGFβ1 is 
elevated in the brain following ALF with subsequent HE development. TGFβ1 binds its 
receptor on neurons leading to subsequent SMAD activation.  This results in increased 
CCL3 protein expression and release, which binds CCR1 on microglia.  Increased CCR1 
activity was found to increase ERK1/2 and NF-κB activity.  Both of these pathways have 
been shown to increase proinflammatory cytokine expression and release in microglia. 
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inflammation by recruitment of CD4+ T cells to the liver, which was found to 
promote liver failure(170).  This shift in immune cell populations in the liver 
following damage has also been observed in patients with liver failure who have 
suppressed circulating CD3+ and CD8+ T cells and increased monocyte 
populations(171).  Also, CCL3 upregulation was found to occur in the liver 
following methionine and choline deficient diets, which has been demonstrated 
to promote liver damage with subsequent fibrosis(172).  Interestingly, low 
concentrations of ammonia, similar to what would be found in the circulation 
during HE, are able to impair neutrophil chemotaxis, phagocytosis, and causes 
them to generate reactive oxygen species(173, 174).  Also, CCL3 has been 
shown to promote the chemotaxis of monocytes and neutrophils(175).  These 
findings, combined with BBB disruption during HE, give support that systemic 
inflammatory cells, such as neutrophils, could be recruited to the brain via CCL3 
and this could worsen HE pathology. 
 Chemokine receptors are seven-transmembrane G-protein coupled 
receptors (GPCRs) that can transduce their signals through multiple 
ligands(176). CCR1-mediated signaling is transduced downstream via Gi/Go 
GPCR signal transduction leading to increased activity of NF-κB, ERK1/2, and 
other signaling proteins(177, 178).  Microglial activation of the proinflammatory 
cytokine IL-6 has been demonstrated to be dependent upon ERK1/2 and NF-κB 
signaling(179).  Our study found that CCR1 protein expression was not changed 
during HE, but that downstream CCR1 signaling mediators were activated.  
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These findings were not surprising as increased CCL3 ligand activity can 
promote increased receptor activity without an increase in the expression of the 
receptor itself.  These findings do not rule out the role of other GPCR-mediated 
signaling pathways in generating HE pathology and is an area that warrants 
further investigation. 
 Previous studies in our laboratory have found that inhibition of circulating 
TGFβ1 is protective.  The current study added one potential mechanism that 
allows TGFβ1 to drive HE pathology, which was the upregulation of CCL3 
expression and increased CCR1 signaling activity.  Interestingly, TGFβ1 is 
generally thought to be anti-inflammatory and has been shown to induce 
neuroprotective factors in the brain like BDNF(180).  Also, knockout of TGFβ1 
was found to increase neuronal cell death and increased microgliosis following 
excitotoxic injury(181).  This anti-inflammatory effect of TGFβ1 has been 
observed in our lab when primary neurons, astrocytes, and microglia were 
treated with rTGFβ1 and we observed decreased cytokine/chemokine 
expression (unpublished observations).  Thus, the effect of TGFβ1 observed in 
the AOM model may be reliant on effects on the liver-brain-inflammation 
signaling axes to generate its deleterious effects, which cannot be observed in 
vitro. 
 Systemic knockout of CCL3 gene expression demonstrated no significant 
change in HE pathology.  This finding could be caused by multiple factors.  
Firstly, these mice have had CCL3 activity knocked out systemically from 
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conception, and as such it is conceivable that they have a compensatory 
upregulation in a number of other chemokines.  In support of this, we have 
preliminary data to suggest that the CCL3 knockout mice have elevated 
expression of CCL2, a chemokine we have shown to be involved in the 
pathogenesis of HE (McMillin and DeMorrow, unpublished observation).  
Secondly, CCL3 is not the only chemokine that binds CCR1 as CCL5, CCL6, 
CCL9, CCL15, and CCL23 have also been shown to have affinity for CCR1 and 
could potentially be upregulated to rescue the effects of CCL3 knockout(182).  
Also, it is possible that the inflammatory processes that occur in the liver and in 
the brain during ALF are dependent upon divergent chemokine signaling and 
thus systemic knockout could be protective for one organ while being deleterious 
for the other.  The final possibility is that a completely separate signal is leading 
to the activation and microgliosis that was observed following development of 
HE.  Thus, there are multiple possibilities as to why systemic knockout of CCL3 
did not generate effects in this model and continued studies in this area will be 
needed to fully identify the specific role of this chemokine during HE. 
 In conclusion, the following study found that CCL3/CCR1 signaling is 
activated during HE and that inhibition of TGFβ1 reduces activity of this 
signaling pathway, microglia activation, and microgliosis.  Together, this 
identifies that TGFβ1 could be exerting its deleterious effect during HE through 
increasing CCL3/CCR1 signaling though more research in this area is needed to 
conclusively identify the role of CCL3 in HE. 
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5.  CONCLUSIONS 
 
Liver failure from both acute and chronic hepatic insults can lead to 
significant disruptions in metabolic homeostasis and subsequent pathology 
outside of the liver.  One of the most difficult complications to address clinically 
is the development of HE.  Multiple pathological mechanisms can lead to the 
initiation of HE to include increases in circulating ammonia and exacerbated 
systemic and central inflammation.  One clinical challenge in this disease is that 
few treatment options are efficacious for patients who progress to grade 3 or 
grade 4 HE with liver transplantation being the only effective option 
available(183).  However, liver transplantation comes with its own risks, as most 
clinical measures of neurological and hepatic function do not correlate well with 
patient outcomes(184).  In addition liver transplantation costs are high with 
limited supplies, which causes many patients to succumb to the disease prior to 
transplantation.  Thus, there is a great need to develop new therapeutics to 
subvert transplantation or slow disease progression so patients can remain 
eligible for transplantation for longer periods of time. 
 In order to identify novel therapeutic targets for the management of HE, 
studies are needed to investigate outside of the current treatment paradigms as 
this has led to few recent advances in therapeutic development.  In fact, 
therapies aimed to reduce ammonia are still relatively unproven with some 
studies showing no benefit on HE(185).  Studies into inflammation have been 
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slightly more fruitful with research into N-acetylcysteine being shown to improve 
survival of patients with HE grade 3-4(186).  Also, hepatectomy with portacaval 
shunting has been used in specialized centers when patients will succumb to HE 
prior to transplantation with one study demonstrating that this allowed for 19 out 
of 32 patients to be successfully transplanted(187).  This strategy has been 
found to reduce intracranial pressure and liver-derived proinflammatory 
cytokines giving support that liver-derived immune signaling plays a role in 
increasing brain pathology(188).  However, inflammation is associated with 
many stimuli and cell signaling mediators, so the purpose of the current 
dissertation was to delineate the role of two signaling proteins released from the 
liver following damage, Shh and TGFβ1, and their effects on HE pathogenesis. 
 Initially, investigations into downstream hedgehog signaling began with 
experiments aimed to assess and manipulate the transcription factor Gli1.  Gli1 
was found to be upregulated in the cortex of AOM-treated mice, 4-week BDL 
rats, and cirrhotic patients with HE.  Also, the use of Vivo-morpholinos against 
Gli1 was found to exacerbate pathology.  This finding supports what has been 
previously demonstrated in other neuropathies with Gli1 being shown to be 
protective in Parkinson’s disease and stroke(93, 94).  One area that we did not 
pursue in these studies was the signaling pathway that contributed to the 
upregulation of Gli1.  Due to the fact that hedgehog suppression only mildly 
reduced Gli1 activation and TGFβ1 was found to suppress Gli1, we did not 
identify other factors in these studies that contributed to Gli1 activation.  Other 
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researchers have identified that Gli1 has the ability to be activated by PI3K/Akt 
signaling and can be downregulated by protein kinase A and Notch/HES/HEY 
signaling(97).  This opens the possibility that upregulation and downregulation of 
these signaling pathways may be potential mechanisms driving the effects that 
we observed.  Identifying the source of Gli1 upregulation is an area that needs to 
be further investigated during HE, as this could be a primary pathway that is 
leading to neuroprotection during this disease. 
 Interestingly, the rationale for pursuing this research on liver-brain axis 
signaling during HE was built upon multiple studies on hedgehog signaling, yet 
methods that we employed to suppress circulating and central Shh/smoothened 
axis signaling were found to have no effect during HE.  These findings are very 
surprising, especially since Gli1 was determined to be neuroprotective.  That 
being said, there are studies that have shown that there is increased regulation 
of Shh/smoothened outside of the traditional signaling pathway.  Smoothened is 
currently thought to act in a similar manner to a G-protein coupled receptor and 
has the ability to activate Gα signaling(189).  Also, smoothened activity may be 
repressed by increases in GTPase activity, which has been demonstrated to be 
caused by increased activity of regulator of G-protein signaling 5(190).  Due to 
the fact that G-protein coupled receptor signaling pathways are modulated by a 
multitude of ligands and other factors, there is support that independent 
modulation of smoothened is not an effective approach to attempt to alleviate 
HE pathology.  It is conceivable that G-protein coupled receptor-mediated 
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signaling plays a significant role during HE, but to identify the specific factors 
stimulating these signaling events in vivo is quite difficult.  For this reason, we 
can state that Shh/smoothened axis signaling seems to play a minimal role in 
HE pathology when investigated as a stand-alone signaling pathway.  Future 
studies will need to be performed to better understand this signaling axis and the 
factors that regulate this signaling pathway. 
 Due to the fact that Shh/smoothened signaling had essentially no effect 
on HE pathology, our focus shifted towards TGFβ1 as it has been demonstrated 
to activate Gli1 signaling(98).  In addition to this, TGFβ1 is found to be have 
increased expression in the liver and is increased in the circulation following liver 
damage(82, 87).  Our idea was that elevation of TGFβ1 was leading to 
increased paracrine signaling outside the liver and strategies to reduce 
circulating levels of TGFβ1 would help restore homeostasis and reduce HE 
pathology.  There is some evidence that reducing TGFβ1 is protective in the 
liver, as systemic delivery of TGFβ siRNA has been found to reduce liver 
cirrhosis pathology(191).  Initial assessments identified that TGFβ1 expression 
was increased in the liver, circulation, and brain following AOM injection.  The 
use of neutralizing antibodies did not generate any significant effects on liver 
damage as measured by H&E stains or liver biochemistry, which was surprising 
and demonstrated that the protective effects of TGFβ1 suppression in the liver 
may not be observed in severe acute hepatotoxin models.  That being said, 
neutralizing TGFβ actually led to increased Gli1 mRNA expression and nuclear 
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translocation, which correlated to reduced neurological decline.  Thus, our 
findings indicated that TGFβ1 was neuroprotective as it reduced neurological 
decline with no apparent effects on liver damage or function. 
 In order to investigate how TGFβ1 could be directly influencing 
neuropathological processes during HE, it would first need to pass through the 
BBB in order to generate any effect.  Research into BBB function following HE 
development has demonstrated that vasogenic brain edema is observed and 
has also been shown to be present in the AOM model(132).  While there are 
some investigations into mechanisms that promote vasogenic edema in the 
brain during HE, none have investigated TGFβ1.  Outside of the brain, TGFβ1 
signaling has been shown to promote vascular permeability, so it is entirely 
feasible that increased BBB permeability during HE could be caused by this 
protein(192).  Our findings identified that BBB is disrupted in vivo following 18 
hours of AOM treatment and that inhibition of TGFβ1 via neutralizing antibodies 
was protective in vivo by reducing Evan’s blue dye presence in the brain.  In 
order to better identify the specific effects of TGFβ1 on BBB permeability we 
employed bEnd.3 cells to investigate monolayer permeability and cell signaling 
events that occur following treatment with recombinant protein.  TGFβ1 was 
found to increase monolayer permeability, downregulate Claudin-5 expression 
and upregulate MMP9 and that these effects could be reversed via inhibition of 
SMAD3.  These effects generated by TGFβ1 support that this protein has the 
ability to open pores in the BBB and could explain the in vivo effects of our AOM 
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model.  Due to the fact that the treatment of AOM mice with neutralizing 
antibodies against TGFβ did not fully recover BBB permeability, there is 
evidence for TGFβ1 acting in synergism with other factors to exacerbate 
permeability of the BBB.  There is extensive evidence that ammonia alters 
passage of amino acids and other proteins across the BBB but does not induce 
the formation of large pores(193).  However, exacerbated inflammatory 
mediators such as TNFα have been demonstrated to open pores and potentiate 
BBB permeability during HE(194).  Thus, it is entirely possible that interactions 
between TGFβ1 and other inflammatory mediators are the primary factors 
affecting BBB permeability during HE, but more studies in this area are still 
warranted.   
 Chemokines have not been identified to play a prominent role in 
inflammation during HE but have been demonstrated to be involved in liver 
injury.  CCL2 has been demonstrated to recruit macrophages to the liver during 
CCl4-induced chronic liver injury and following methionine-choline-deficient diet-
induced liver injury(195).  Also, hepatic CCL2 expression and plasma circulating 
levels are increased during alcoholic liver disease and this correlates with 
neutrophil infiltration(196).  In regards to ALF, patients with liver failure have 
increased levels of multiple chemokines to include CCL2, CCL3, CCL4, and 
CCL5 in both the liver and serum(197).  Initially, we began our studies 
investigating CCL3/CCR1 signaling in the brain as there are currently no 
manuscripts that have specifically investigated this signaling pathway following 
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HE development.  The subsequent experiments identified that the chemokine 
CCL3 was upregulated during HE and that its receptor, CCR1, had increased 
activity.  In addition to this it was determined that inhibition of TGFβ1 was able to 
inhibit the upregulation of CCL3 protein in the brain and reduce microglia 
activation.  Interestingly, the genetic knockout of CCL3 was found to have no 
effect on HE pathology.  While puzzling, a recent report found that both CCL2 
and CCL3 are increased in the liver following acetaminophen-induced liver 
failure and help recruit monocytes to the liver(198).  Also, CCL2 expression has 
been demonstrated to be increased in the brains of mice following peripheral 
organ inflammation caused by BDL-induced liver injury(199).  These studies 
gave us the idea that systemic knockout of CCL3 may lead to compensatory 
recovery of function via upregulation of CCL2.  We have generated preliminary 
data that demonstrates that following CCL3 knockout, cortical CCL2 mRNA 
expression is upregulated.  Furthermore, mice that had systemic injections of 
antagonists against CCR2 of CCR4, the receptors for CCL2, prior to AOM 
injection had significantly improved neurological outcomes.  The current effects 
of TGFβ1 and its interaction with CCL2, as well as how CCL2/CCL3 
independently affect pathology during HE, are still being investigated and are an 
area of future studies in the lab.       
In summary this body of work described novel findings in regards to cell 
signaling and HE pathology.  First of all, it was found that circulating TGFβ1 
suppressed the neuroprotective transcription factor Gli1 in the brain and 
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exacerbated HE.  Secondly, TGFβ1 was able to permeabilize the BBB via 
upregulation of MMP9 and downregulation of Claudin-5 in brain endothelial cells.  
Finally, it was determined that TGFβ1 was able to activate microglia, generated 
microgliosis, and upregulated CCL3/CCR1 signaling following development of 
HE.  Thus, these findings demonstrate that TGFβ1 is a pathological signaling 
protein with direct involvement in HE pathogenesis via downregulation of 
neuroprotective Gli1, exacerbating BBB permeability, and promoting microglial 
activation and microgliosis (a working model of these findings is presented 
below in figure 26).  More importantly, however, is that this identifies that 
signaling proteins that are upregulated following liver damage have the potential 
to generate distant paracrine signaling that can contribute to HE pathology.  This 
allows for a change in perspective in regards to research into HE, as previous 
studies have focused on toxic metabolites and inflammation without direct 
investigations into cell signaling pathways. 
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Fig. 26.  Overall working model of TGFβ1 signaling.  Toxin insult or liver disease leads to 
an upregulation of TGFβ1 in the liver and circulation.  This leads to Claudin-5 disruption at 
the BBB and causes endothelial cells to secrete MMP9 exacerbating BBB permeability.  
This allows the entry of TGFβ1 into the brain where it suppresses the neuroprotective 
transcription factor Gli1, increases CCL3 expression, and activates microglia.  Together, 
these processes lead to a significant increase of HE pathology. 
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